ASBMR

Is Retinal Microvascular Abnormalities an Independent Risk Factor of Vertebral Fractures? A Prospective Study From a Chinese Population

Junping Wen,^{1*} Kaka Tang,^{1*} Fengye Zhu,^{1*} Wei Lin,^{1*} Huiying Rao,^{2*} Huibin Huang,¹ Jin Yao,¹ Ling Chen,¹ Jixing Liang,¹ Lixiang Lin,¹ Hongjie Chen,¹ Meizhi Li,¹ Xueying Gong,¹ Shushan Peng,¹ Jieli Lu,³ Yufang Bi,³ Weiqing Wang,³ Guang Ning,³ Pengli Zhu,⁴ and Gang Chen¹

¹Department of Endocrinology, Fujian Provincial Hospital Key Laboratory of Endocrinology, Fujian Medical University, Fuzhou, China

²Department of Ophthalmology, Fujian Provincial Hospital, Fujian Medical University, Fuzhou, China

³Department of Endocrinology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

⁴Department of Geriatrics, Fujian Provincial Hospital Key Laboratory of Endocrinology, Fujian Medical University, Fuzhou, China

ABSTRACT

Low bone mineral density (BMD) and microvascular diseases (MVD) share various common risk factors; however, whether MVD is an independent risk factor of vertebral fractures is incompletely understood. The aim of this study is to clarify whether MVD is an independent risk factor of vertebral fractures. In this prospective study, calcaneal BMD and retinal microvascular abnormalities were assessed at baseline from June 2011 to January 2012. A total of 2176 premenopausal women, 2633 postmenopausal women, 2998 men aged <65 years, and 737 men aged ≥65 were included. Then with/without retinal microvascular abnormalities cohorts were followed for an average of 2.93 years to find out the relationship between MVD and vertebral fractures. At the baseline, after full adjustment, retinal microvascular abnormalities were related to risk of low BMD only in men aged 265 years (odds ratio [OR] = 2.506; 95% confidence interval [CI] 1.454-4.321; p = 0.001). After follow-up of 2.93 years, retinal microvascular abnormalities were related to risk of vertebral fractures in men aged >65 years (OR = 2.475; 95% CI 1.085–5.646; p = 0.031) when adjustment for confounding factors. However, no associations were found between MVD and vertebral fractures in men aged <65 years, premenopausal women, and postmenopausal women. When stratified by diabetes, in the without-diabetes group, the men with retinal microvascular abnormalities had higher risk for vertebral fractures than without retinopathy (OR = 2.194; 95% CI 1.097–4.389; p = 0.026); however, the difference was not found in women. In the diabetes group, there were no significant differences of risk for vertebral fractures between those with retinal microvascular abnormalities and those without both in men and women. Stratified by hypertension, the men with retinopathy had higher risk for vertebral fractures than those without among the hypertension group (OR = 2.034; 95% Cl 1.163–3.559; p = 0.013), but a difference was not found among women. In the without-hypertension group, no relation was found between MVD and fracture both in men and women. In conclusion, MVD is an independent risk factor of vertebral fractures in old men. © 2017 The Authors. JBMR Plus is published by Wiley Periodicals, Inc. on behalf of the American Society for Bone and Mineral Research.

KEY WORDS: OSTEOPOROSIS; GENERAL POPULATION STUDIES; BONE MINERAL DENSITY (BMD); RETINAL MICROVASCULAR ABNORMALITIES; VERTEBRAL FRACTURE

Introduction

B one loss and vascular abnormalities both occur insidiously and are initially asymptomatic processes that increase markedly with advancing age. As the number of elderly increases, so will the magnitude of the problem. Multiple factors including proteins, parathyroid hormone (PTH), phosphate, oxidized lipids, and vitamins D and K are implicated in both bone and vascular metabolism, illustrating the interaction of these two seemingly unrelated conditions.⁽¹⁾ Some study has shown that diabetic microvascular complications contribute to risk of fracture.^(2,3) For people who do not suffer from diabetes or hypertension with microvascular disease (MVD), the risk for fracture remains elusive. In addition, the association between MVD and fracture in large prospective study is limited. Evidence linking fragile fracture with microvascular complications in bone remains incompletely understood.

Received in original form January 30, 2017; revised form July 9, 2017; accepted August 15, 2017. Accepted manuscript online August 18, 2017.

Address correspondence to: Gang Chen, MD, PhD, and Pengli Zhu, MD. E-mail: chengangfj@163.com; penlizhu_fz@163.com *JW, KT, FZ, WL, and HR contributed to the study equally.

JBMR Plus, Vol. 1, No. 2, October 2017, pp 107-115

DOI: 10.1002/jbm4.10017

© 2017 The Authors. JBMR Plus is published by Wiley Periodicals, Inc. on behalf of the American Society for Bone and Mineral Research

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Additional supporting information may be found in the online version of this article at the publisher's web-site.

It is a well-established principle that blood supply to the bone is a vital basis of bone growth and remodeling. Peripheral vascular resistance and the perfusion pressure gradient are two main factors controlling the rate of flow through the microvascular bed.⁽⁴⁾ Reduced blood flow has been linked low bone mass disorders. Two studies^(5,6) have found that a special capillary subtype (CD31hi/Emcnhi vessels) and Notch signaling pathway are involved in the murine bone growth. The decline of CD31hi/ Emcnhi vessels and the concomitant reduction of osteoprogenitor cells could potentially offer a compelling explanation for bone loss during aging.⁽⁵⁾ For technical difficulties, the precise overall structure of the skeletal vasculature in human has remained poorly understood. The human eye offers an excellent opportunity to visualize the microcirculation. Direct ophthalmoscopic examination provides a noninvasive means by which MVD can be assessed in vitro, and because the anatomy and physiology of retinal arterioles are similar to those of cerebral and coronary arterioles, retinal microcirculation abnormalities may reflect generalized microcirculatory pathology.^(7,8) The spatial distribution of arteriole-capillary connections determines regional differences in oxygenation and metabolic activity in bone.⁽⁵⁾ Calcaneal quantitative ultrasound (QUS) is a quick, simple, and inexpensive method free of ionizing radiation that appears to be effective in detecting bone loss.⁽⁹⁾ A great deal of literature⁽¹⁰⁻²¹⁾</sup> have shown that severe height loss (at least 2 cm</sup>over 3 to 7 years) is often a consequence of osteoporotic vertebral fractures, so we use height loss of at least 2 cm as a surrogate of vertebral fragile fractures.

Estrogen and age have a significant impact on bone mineral density $(BMD)^{(22)}$ and vascularization.⁽²³⁾ Therefore, we evaluate the different associations of microvascular abnormalities with bone loss/fracture among premenopausal women, postmenopausal women, men aged <65 years, and men aged \geq 65 years. Because diabetes and hypertension can cause microangiopathy, we further categorized diabetic, hypertensive, and sex to explore the relations between the microvascular and vertebral fragile fractures.

Materials and Methods

See the Supplemental Methods for more detail.

Study cohort

This was a prospective observational cohorts study design is shown in reference 24 and supplemental material.⁽²⁴⁾ A total of 10,906 Chinese responded to the survey who were not pregnant and had no cognitive dysfunction. Among them, 1876 subjects who refused to undergo retinal examination or were temporally outside, 165 with history of thyroid disorders, hypercortisolism, rheumatoid arthritis, or use of medications known to influence bone strength (ie, drugs for osteoporosis, thiazide diuretic, oral contraceptives, or glucocorticoids therapy), and 321 with missing laboratory data were excluded. The final analytic baseline sample included 8544 self-identified Hans aged 40 to 89 years (49.8% rural; 56.3% women). Then baseline population was categorized into two groups, microvascular abnormalities and without microvascular abnormalities, according to the retinal examination result to follow. Three-year follow-up visits were conducted between August 2014 and November 2014. A total of 5058 participants were included in the final analysis, after excluding 178 individuals who had a history of thyroid disorders, hypercortisolism, rheumatoid arthritis, or use of medications

known to influence bone strength (ie, drugs for osteoporosis, thiazide diuretics, oral contraceptives, or glucocorticoids therapy), and missing laboratory data and 13 subjects with a self-reported history of vertebral trauma during the follow-up (Fig. 1). Written informed consent was obtained from every participant, and the study has been approved by the Institutional Review Board of Fujian Provincial Hospital. All investigators received special training and were unaware of the aims of the study and were blinded to the characteristics of the subjects.

Baseline assessment

BMD was assessed by scanning the left calcaneus with Sahara (Hologic, Inc., Waltham, MA, USA). All the parameters were measured twice by the same experienced operator, and the mean value was used for analysis. Results for calcaneal BMD were transformed to *T*-scores (calculated as the difference between the actual measurement and the mean value of healthy sex-matched adult controls, divided by their standard deviation), from the data provided by the densitometer manufacturer. According to the World Health Organization (WHO) criteria,⁽²⁵⁾ bone status was categorized into three groups: normal BMD (*T*-score ≥ -0.9), osteopenia ($-2.4 \leq T$ -score ≤ -1.0), or osteoporosis (*T*-score ≤ -2.5). Low BMD refers to T-score ≤ -1.0 .

Direct ophthalmoscopic examination from both eyes after 5 minutes of dark adaptation was conducted by two qualified retinal ophthalmologists independently. A research ophthalmologist undertook a quality assurance check of 10% of the diagnosis and no instances of discordance were identified. Microvascular abnormalities were defined as present if any of the following lesions were observed in any of the four fundus quadrants: microaneurysms, retinal hemorrhages (blot or flame shaped), soft exudates (cotton-wool spots), hard exudates, macular edema, intraretinal microvascular abnormalities, venous beading, new vessels at the disc or elsewhere, vitreous hemorrhage, disc swelling, laser photocoagulation scars, arteriovenous nicking, or focal arteriolar narrowing.

Standing height was measured in light clothing without shoes with the use of an electronic stadiometer. Subjects placed both heels, buttocks, and their back against the stadiometer backboard, with the head positioned in the Frankfort horizontal plane. The participants were instructed to stretch to a fully erect position while keeping the feet flat on the floor. Excessive stretching was avoided. Besides the subjects' heads being maintained in the Frankfort plane, the heads did not necessarily touch the backboard. The horizontal plate of the stadiometer was pressed firmly onto the heads, flattening the hair. Height was measured by certified nurses to the nearest 0.1 cm during normal respiration.⁽¹⁶⁾

A questionnaire including information on demographic characteristics, medical history, and lifestyle factors was administered. Anthropometric measurements were conducted. Body mass index (BMI) was calculated as weight (kg) divided by height (m) squared. Standard laboratory tests determined blood glucose, HbA1c, serum insulin, creatinine, and lipids. The index of homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as: fasting glucose (mmol/L) × fasting insulin (μ U/mL)/22.5.⁽²⁶⁾ The CKD-EPI equation was used to estimate glomerular filtration rate (eGFR).⁽²⁷⁾ Age is divided into four groups: \leq 45, 46 to 55, 56 to 65, and >65 years.

Diabetes mellitus was defined as having fasting blood glucose (FBG) \geq 7.0 mmol/L, porphobilinogen (PBG) \geq 11.1 mmol/L, or



Fig. 1. Study flow diagram.

history of treatment for diabetes. Insulin resistance (IR) was defined as HOMA-IR higher than 2.50.⁽²⁸⁾ Hypertension was defined as having systolic blood pressure (SBP) \geq 140 mmHg, diastolic blood pressure (DBP) \geq 90 mmHg, or history of treatment for hypertension. Dyslipidemia was defined as current treatment with cholesterol-lowering medication or having one or more of the following: TC > 6.22 mmol/L, TG > 2.26 mmol/L, LDL > 4.4 mmol/L, and HDL < 1.04 mmol/L.⁽²⁹⁾ Furthermore, general obesity was defined as BMI \geq 27.5 kg/m⁽²⁾ and abdominal obesity as waist circumference (WC) \geq 90 cm for men and \geq 80 cm for women.^(30,31) We defined abnormal eGFR as <60 mL/min/1.73 m².⁽³²⁾

Collection of follow-up data

Three-year follow-up visits measured height. Height loss of at least 2 cm over 3 years was an indication of vertebral fractures. Subjects self-reported any history of trauma fracture(s), details of the way, site, and date. Methods of followed data collection were similar to the baseline. However, direct ophthalmoscopic examination and fasting insulin were not collected in the follow-up visit. In addition, Calcaneal quantitative ultrasound was followed only in Wuyishan city.

Statistical analysis

EpiData software (The EpiData Association, Odense, Denmark) was used to establish the database. All data were double entered in a database and then compared and corrected for errors. Continuous variables were shown by medians with interquartile ranges (IQR; the range between the 25th and 75th percentile) because of the non-normal distribution, and categorical variables were expressed by counts and percentages. The differences among subjects in different groups were detected using the Kruskal-Wallis test for continuous variables and chi-square test for categorical variables. Constructing multiple logistic regression models determined the relationship between low BMD and microvascular abnormalities on baseline. First, the

crude associations were evaluated (unadjusted) and then included adjustment for age (model 1). Subsequent models were built with inclusions of education, physical activity, smoking status, alcohol, coffee, milk, and bean products consumption (model 2), then further adjusted for diabetes, IR, hypertension, dyslipidemia, eGFR < 60 mL/min/1.73 m², generalized and abdominal obesity, gastrointestinal disorders, respiratory diseases, and urological diseases (model 3). Additionally, binary logistic regression was used to analyze the association between vertebral fractures and microvascular abnormalities. The detailed process of adjusted confounding factors is given in Table 3. To further control the effects of diabetes mellitus and hypertension, data were split into diabetes mellitus and hypertension, in men and women, and the risk of vertebral fragile fractures with microvascular abnormalities were compared to without microvascular abnormalities by binary logistic regressions.

All data analyses were performed with SPSS 19.0 statistical software package (SPSS, Chicago, IL, USA). All p values were based on two-sided tests, with statistical significance defined as p < 0.05.

Results

At baseline, participants were randomly selected, with 56.3% being women and 43.7% being men, giving a sex ratio of 1.29:1, with a total median age of 53 years (IQR, 46 to 61 years). Prevalence of retinal microvascular abnormalities was 1.3%, 2.9%, 6.9%, and 9.6% in premenopausal women, men aged \geq 65 years, postmenopausal women, and men aged \geq 65 years, respectively, and low BMD prevalence was 10.7%, 28.3%, 40.6%, and 43.8% (Supplemental Table S1). The baseline measures, follow-up measures, and percentage change in subjects with and without microvascular abnormalities are shown in Table 1. In the microvascular abnormalities group, the prevalence of vertebral fractures was 22.2%, 24.6%, 22.8%, and 39.5% among premenopausal women, men aged <65 years, postmenopausal

Table 1. Sex-Specific Baseline and Followed-up Characteristics

Without retinopathy p Without With retinopathy p Without Value Without retinopathy p With retinopathy Value Baseline Number 3577 158 4598 211 Age (yars) 324 (51 to 62) 63 (55 to 68) 0.001 51 (46 to 52) 62 (57 to 66) 0.001 Smokers 1709 (49.0) 106 (67.0) 0.006 1205 (2.2.1) 40 (19.0) 0.001 Coffee drinkers 189 (33.2) 63 (39.9) 0.066 1205 (2.2.1) 40 (19.0) 0.001 Coffee drinkers 1331 (51.2) 84 (53.2) 0.684 2057 (44.7) 82 (44.5) 0.103 Bean products 2299 (67.1) 123 (77.8) 574 (51 to 5.8) 62 (55 to 5.8) 0.001 Low 2399 (67.1) 123 (77.8) 526 (11.4) 62 (55 to 8.8) 0.001 54 (51 to 5.8) 62 (55 to 8.8) 0.001 High 854 (2.39) 19 (12.0) 526 (11.4) 64 (54 to 8.8) 62 (55 to 8.8) 0.01 57 (54 to 6.0) 63 (57 to 8.3) 62 (55 to 8.8) 0.01 57 (54 to 6.0)		Men			Women		
retinopathy With retinopathy Value retinopathy With retinopathy Value Baseline 3577 158 4999 211 Age (years) 53 (45 to 62) 63 (55 to 68) 0.001 51 (46 to 59) 62 (57 to 68) 0.001 Simokars 1709 (49.8) 106 (67.0) 0.001 28 (6.0) 51 (24.1) 0.001 Caffee drinkers 2109 (57) 6 (3.8) 0.379 309 (67) 62 (25.1) 0.001 Caffee drinkers 204 (57) 6 (3.8) 0.379 309 (67) 62 (25.1) 0.001 Low 2399 (67.1) 123 (77.8) 3744 (81.4) 202 (57.1) 0.001 Moderate 324 (61) 16 (101) 328 (71.1) 3 (1.4) 62 (55.10 0.001 PBG (mmol/L) 6.5 (5.1 to 6.0) 6.2 (5.5 to 7.4) 0.001 6.8 (5.7 to 8.3) 10.8 (7.10.18) 0.001 PBG (mmol/L) 5.3 (5.1 to 6.0) 2.4 (1.2 to 7.4) 0.6 (3.5 to 7.10.3) 10.8 to 1.13) 0.001 PBG (mmol/L) 5.4 (6.1 to 8.2) <td< th=""><th></th><th>Without</th><th></th><th>р</th><th>Without</th><th></th><th>p</th></td<>		Without		р	Without		p
Baseline Number Age (years) 537/5 158 450 2011 Age (years) 537/5 158 000 51 (46 to 59) 62 (57 to 68) 0001 Smokers 1709 (49.8) 106 (67.0) 0.001 28 (6.0) 59 (2.6) 0.001 Smokers 1709 (49.8) 106 (67.0) 0.001 28 (6.0) 59 (2.4) 0.001 Coffee drinkers 1248 (4.2) 278 (3.3) 0.379 309 (6.7) 6 (2.8) 0.021 Coffee drinkers 1248 (4.5) 84 (3.2) 0.68 1205 (2.6.) 40 (19.0) 0.001 Coffee drinkers 1248 (4.5) 84 (3.2) 0.68 1205 (2.6.) 40 (19.0) 0.001 Smokers 1248 (4.2) 279 (7.8.2) 118 (7.4.7) 0.281 3661 (80.1) 155 (7.3.5) 0.023 Bean products 2299 (7.1) 123 (77.8) 0.001 Moderate 324 (9.1) 16 (10.1) 238 (7.1) 3 (1.4) High 854 (2.3.9) 19 (12.0) 24 (5.10 58) 0.001 FBG (mmol/L) 55 (5.11 60 6 2.2 (5.10 7.8) 0.001 FBG (mmol/L) 55 (5.11 60 6 2.2 (5.10 7.8) 0.001 FBG (smmol/L) 52 (5.4 to 6.) 62 (5.5 (7.8) 0.001 FBG (smmol/L) 52 (5.4 to 6.) 62 (5.5 (7.8) 0.001 FBG (smmol/L) 52 (5.4 to 6.) 62 (5.5 (7.8) 0.001 FBG (smmol/L) 64 (5.1 to 8.2) 96 (6.8 to 15.4) 0.001 FBA (5.10 58) 24 (2.6 to 7.8) 0.001 FBA (5.10 58) 24 (2.6 to 1.5.0) 0.001 FBA (5.10 58) 24 (2.6 to 3.7) 0.001 FBA (5.10 58) 24 (3.10 5.0) 0.001 FBA (5.10 58) 24 (3.10 5.0) 0.001 FBA (5.10 58) 24 (3.10 5.0) 0.001 FBA (5.10 58) 74 (1.5 0.7) 0.001 FBA (5.10 59) 75 (4.8 to 5.1) 0.001 FBA (5.10 59) 76 (3.10 59) 77 (1.0 1.0) FBA (5.10 59) 76 (3.10 59) 77 (1.0 1.0) FB		retinopathy	With retinopathy	Value	retinopathy	With retinopathy	Value
Number 3577 158 4598 211 Age (pears) 53 (45 to 63 63 (55 to 68) 0.01 51 (46 to 59) 62 (57 to 68) 0.001 High school or more 1226 (42.9) 278 (37.7) 0.161 921 (42.3) 69 (26.4) 0.013 Alcohol drinkers 1189 (33.2) 63 (39.9) 0.086 1205 (26.2) 40 (19.0) 0.001 Coffee drinkers 1281 (51.2) 84 (53.2) 0.684 2057 (44.7) 82 (44.5) 0.001 Bean products 2299 (78.2) 118 (74.7) 0.281 3641 (80.1) 155 (57.5) 0.001 Low 2399 (67.1) 123 (77.8) 0.001 54 (5.0 to 5.8) 62 (5.5 to 8.8) 0.001 High 854 (23.9) 19 (12.0) 52 (61 to 1.4) 0.001 54 (5.0 to 5.8) 62 (5.5 to 7.8) 0.001 57 (54 to 6.1) 0.001 Hold (rmmol/L) 52 (3.4 to 7.7) 6.5 (4.5 to 7.4) 0.001 57 (54 to 6.8) 6.5 (7 to 8.3) 7.6 (7 to 8.3)<	Baseline						
Age (years) 53 (45 to 62) 63 (55 to 68) 0.001 15 (46 to 59) 62,75 to 68) 0.001 Smokers 1709 (49.8) 106 (67.0) 0.001 28 (6.0) 55 (2.4) 0.010 Smokers 1189 (33.2) 63 (39.9) 0.06 1205 (26.2) 40 (19.0) 0.001 Conder drinkers 128 (12.8) 45 (32.1) 0.64 (24.7) 82 (47.7) 6.001 Moderate 324 (9.1) 16 (10.1) 328 (7.1) 328 (7.1) 62 (5.5 to 8.8) 0.001 54 (5 to 8.8) 1.00 (5.5 to 8.3) 1.08 (7.7 to 1.8) 0.001 FBG (mmol/L) 55 (7 ta 6.6) 62 (5 to 7 ta 4.8) 0.001 57 (5 to 8.0) 0.001 57 (5 to 8.1) 0.001 FBG (mmol/L) 134 (12 ta 14.71	Number	3577	158		4598	211	
High school or more 1285 (42.9) 278 (37.7) 0.161 921 (42.3) 696 (26.4) 0.001 Alcohol drinkers 1189 (33.2) 63 (39.9) 0.086 1205 (26.2) 40 (19.0) 0.001 Coffee drinkers 1281 (51.2) 84 (53.2) 0.684 2057 (44.7) 82 (44.5) 0.002 Bean products 2799 (78.2) 118 (74.7) 0.281 3681 (80.1) 155 (57.35) 0.003 Low 2399 (67.1) 123 (77.8) 3744 (81.4) 202 (95.7) Moderate Moderate 324 (9.1) 16 (10.1) 326 (71.4) 6 (2.6) FBG (mmol/L) 64 (5.1 to 8.2) 96 (6.8 to 15.4) 0.001 6.4 (5.1 to 8.3) 0.001 PBG (mmol/L) 5.7 (5.4 to 0.6) 6.2 (5.7 to 7.4) 0.001 5.7 (5.4 to 0.3) 0.001 FMG (12/mml) 13 (14 to 7.7) 6.5 (4.3 to 9.8) 0.001 5.7 (5.4 to 0.3) 0.001 PBG (mmol/L) 5.1 (4.4 to 5.2) 5.1 (4.2 to 1.6) 0.01 5.7 (5.4 to 0.3) 0.01 5.7 (5.4 to 0.3) 0.01 5.7 (1.1 to 1.5) 0.02	Age (years)	53 (45 to 62)	63 (55 to 68)	0.001	51 (46 to 59)	62 (57 to 68)	0.001
Smokers 1709 (49.8) 106 (67.0) 0.001 28 (6.0) 5 (2.4) 0.013 Alcohol drinkers 1189 (32.) 63 (39.9) 0.086 1205 (2.5.) 40 (10.0) 0.001 Coffee drinkers 128 (15.2) 84 (5.2.) 0.684 2057 (44.7) 82 (44.5) 0.033 Bean products 2799 (7.2.) 118 (74.7) 0.281 3681 (80.1) 361 (80.1) 361 (80.1) 31 (4) High 654 (23.9) 19 (12.0) 526 (11.4) 6 (2.6) 62 (5.5 to 7.8) 0.001 54 (5.0 to 5.8) 6.2 (5.5 to 7.8) 0.001 54 (5.0 to 5.8) 6.2 (5.5 to 7.8) 0.001 54 (5.0 to 8.8) 0.001 HbG (mmol/L) 5.2 (5.1 to 7.8) 0.001 5.7 (5.4 to 6.8) 6.3 (57 to 8.1) 0.001 154 (11.5 to 1.3) 1.001 154 (11.5 to 1.3) 1.001 HbM (mhl) 5.2 (3.5 to 7.8) 0.001 1.2 (11.5 to 3.4) 0.001 124 (11.5 to 1.3) 0.001 124 (11.5 to 1.3) 0.001 124 (11.5 to 3.4) 0.001 HbG (mmol/L) 1.3 (1.5 to 7.7 (5.1 (5.4 to 7.8) <t< td=""><td>High school or more</td><td>1285 (42.9)</td><td>278 (37.7)</td><td>0.161</td><td>921 (42.3)</td><td>696 (26.4)</td><td>0.001</td></t<>	High school or more	1285 (42.9)	278 (37.7)	0.161	921 (42.3)	696 (26.4)	0.001
Alcohol drinkers 1189 (33.2) 63 (39.9) 0.086 1205 (26.2) 40 (19.0) 0.001 Coffee drinkers 1231 (51.2) 84 (53.2) 0.684 2057 (44.7) 82 (44.5) 0.103 Bean products 2799 (72.2) 118 (74.7) 0.281 3681 (80.1) 155 (73.5) 0.023 Physical activity 0.001 564 (14.4) 62 (25.7) 0.001 564 (14.4) 62 (25.7) 0.001 Low 2399 (67.1) 123 (77.8) 0.001 5.7 (5.4 to 6.0) 62 (5.5 to 7.8) 0.001 5.7 (5.4 to 6.0) 62 (5.5 to 7.8) 0.001 5.7 (5.4 to 6.0) 62 (5.5 to 7.8) 0.001 1.5 (1.1 to 1.2) 1.8 (7.7 to 1.1.8) 0.001 FBG (mmm/L) 5.7 (5.4 to 6.0) 6.2 (5.5 to 7.8) 0.001 1.5 (1.1 to 1.2) 0.2 (2.1 to 3.4) 0.001 FMG (mm/L) 5.7 (5.4 to 6.0) 6.2 (5.5 to 7.8) 0.001 1.5 (1.1 to 1.2) 0.01 1.5 (1.1 to 1.3) 0.001 1.5 (1.1 to 1.3) 0.01	Smokers	1709 (49.8)	106 (67.0)	0.001	28 (6.0)	5 (2.4)	0.013
Coffee drinkers 204 (5.7) 6 (3.8) 0.379 309 (6.7) 6 (2.8) 0.022 Milk drinkers 1831 (51.2) 84 (53.2) 0.684 2057 (44.7) 82 (44.5) 0.031 Bean products 2799 (78.2) 118 (74.7) 0.281 3681 (80.1) 155 (73.5) 0.022 Moderate 324 (91.) 16 (10.1) 328 (7.1) 3 (1.4) 6 (2.6) FBG (mmol/L) 5.5 (5.1 to 6.0) 6.2 (5.5 to 7.8) 0.001 5.4 (5.0 to 8.3) 0.28 (5.1 to 8.1) 0.001 HbA1 (7%) 5.7 (5.4 to 6.0) 6.2 (5.7 to 7.4) 0.001 5.7 (5.4 to 6.3) 6.3 (5.7 to 8.1) 0.001 HOM-AR 1.3 (0.8 to 2.0) 2.1 (1.2 to 3.0) 0.001 1.5 (1.1 to 2.2) 2.2 (1.5 to 3.4) 0.001 DBP (mmHg) 174 (72 to 86) 85 (76 to 91) 0.001 1.27 (117 to 1.4) 1.4 (1.2 to 1.6) 0.4 to 1.7) 0.21 (1.1 to 1.5) 0.01 2.7 (1.2 to 1.6) 0.3 (2.2 to 3.3) 0.01 DBM (mmbg) 7.8 (72 to 8.6) 85 (76 to 91) 0.001 2.2 (1.2 to 1.6) 0.001	Alcohol drinkers	1189 (33.2)	63 (39.9)	0.086	1205 (26.2)	40 (19.0)	0.001
Milk drinkers 1831 (51.2) 84 (53.2) 0.684 2057 (44.7) 82 (44.5) 0.103 Physical activity 0.001 <td>Coffee drinkers</td> <td>204 (5.7)</td> <td>6 (3.8)</td> <td>0.379</td> <td>309 (6.7)</td> <td>6 (2.8)</td> <td>0.022</td>	Coffee drinkers	204 (5.7)	6 (3.8)	0.379	309 (6.7)	6 (2.8)	0.022
Bean products 2799 (78.2) 118 (7.47,) 0.281 3681 (80.1) 155 (75.5) 0.023 Low 2399 (67.1) 123 (77.8) 3744 (81.4) 202 (95.7) 0.001 Moderate 324 (9.1) 16 (10.1) 328 (7.1) 3 (1.4) 6 (2.5) PBG (mmol/L) 6.4 (5.1 to 6.0) 6.2 (5.5 to 7.8) 0.001 5.4 (5.0 to 5.8) 6.2 (5.5 to 7.8) 0.001 HIA (1/WnL) 5.2 (5.1 to 6.0) 6.2 (5.7 to 7.4) 0.001 5.7 (5.4 to 6.0) 6.3 (5.7 to 8.1) 0.001 HOM-AR 1.3 (0.8 to 2.0) 2.1 (1.2 to 3.0) 0.001 1.5 (1.1 to 2.1) 1.4 (1.2 to 1.6) 0.021 DBP (mmHg) 134 (123 to 137) 146 (132 to 159) 0.001 7.6 (17 to 7.4) 145 (2.1 to 1.6) 0.021 C (mmol/L) 1.3 (1.1 to 1.5) 1.3 (1.1 to 1.5) 0.005 1.3 (0.9 to 1.8) 1.6 (2.2 to 2.3) 0.001 TG (mmol/L) 1.4 (1.0 to 2.1) 1.6 (1.1 to 2.5) 0.006 1.3 (0.9 to 1.8) 1.6 (2.2 to 2.3) 0.001 TG (mmol/L) 1.4 (1.0 to 2.1) 1.6 (1.1 to 2.5)	Milk drinkers	1831 (51.2)	84 (53.2)	0.684	2057 (44.7)	82 (44.5)	0.103
Physical activity 0.001 0.001 0.001 0.001 Low 2399 (67.1) 123 (77.8) 3744 (81.4) 202 (95.7) Moderate 324 (9.1) 16 (10.1) 328 (7.1) 3 (1.4) High 854 (23.9) 19 (12.0) 526 (11.4) 6 (2.6) PBG (mmol/L) 6.4 (5.1 to 8.2) 9.6 (6.8 to 15.4) 0.001 5.7 (5.4 to 6.0) 6.3 (5.7 to 8.3) 0.88 (7.7 to 11.8) 0.001 FIM (µL/mL) 5.2 (3.4 to 7.7) 6.5 (4.3 to 9.8) 0.001 6.4 (4.6 to 8.8) 7.6 (5.3 to 11.3) 0.001 HOMA-IR 13 (0.8 to 2.0) 2.1 (1.2 to 3.0) 0.001 1.57 (1 to 7.3) 0.001 DBP (mmHg) 7.8 (7.2 to 8.6) 85 (76 to 91) 0.001 7.6 (5.9 to 8.3) 7.8 (71 to 8.7) 0.018 DL (mmol/L) 1.3 (1.1 to 1.5) 1.3 (1.1 to 1.5) 0.001 2.5 (2.4 to 2.5) 3.1 (2.6 to 2.7) 0.018 TC (mmol/L) 1.4 (1.2 to 1.4) 2.40 (2.1 to 2.5) 2.2 (2.5 to 3.6) 3.1 (2.6 to 2.7) 0.011 TC (mmol/L) 1.4 (1.1 to 1.5) 2.3 (2.5	Bean products	2799 (78.2)	118 (74.7)	0.281	3681 (80.1)	155 (73.5)	0.023
Low 2299 (or.1) 123 (17.8) 3744 (81.4) 202 (95.7) Moderate 322 (7.1) 3 (1.4) High 854 (23.9) 19 (12.0) 526 (11.4) 6 (2.6) PG (mmol/L) 5.5 (5.1 to 6.0) 6.2 (5.5 to 7.8) 0.001 5.4 (5.0 to 5.8) 6.2 (5.5 to 8.8) 0.001 HbA1c (%) 5.7 (5.4 to 6.0) 6.2 (5.7 to 7.4) 0.001 6.8 (5.7 to 8.1) 0.001 HbA1c (%) 5.7 (5.4 to 6.0) 6.2 (5.7 to 7.4) 0.001 5.7 (5.4 to 6.0) 6.3 (5.7 to 8.1) 0.001 HbA1c (%) 5.7 (5.4 to 6.0) 6.2 (5.7 to 7.4) 0.001 1.5 (1.1 to 2.2) 2.2 (1.5 to 3.4) 0.001 HbA1c (%) 7.7 (5.1 to 1.1 to 1.5) 0.001 1.5 (1.1 to 2.2) 2.2 (1.5 to 3.4) 0.001 DBP (mmHg) 78 (72 to 8.6) 85 (76 to 91) 0.001 76 (69 to 8.1) 77 (71 to 8.7) 0.011 DBP (mmHg) 78 (72 to 8.6) 85 (76 to 91) 0.001 76 (69 to 8.1) 77 (71 to 8.7) 0.011 TG (mmol/L) 1.3 (1.1 to 1.5) 1.3 (1.1 to 1.5) 0.005 1.4 (1.2 to 1.6) 1.4 (1.2 to 1.6) 0.237 LDL (mmol/L) 2.9 (2.4 to 3.4) 2.8 (2.3 to 3.4) 0.209 3.0 (2.5 to 3.6) 3.1 (2.6 to 3.7) 0.018 TG (mmol/L) 1.4 (1.1 to 2.1) 1.6 (1.1 to 2.5) 0.006 1.3 (0.9 to 1.8) 1.6 (2.2 to 2.3) 0.001 BMI (kg/m ²) 24.0 (2.1 9 to 2.62) 25.2 (2.3 z to 0.001 23.7 (2.18 to 2.5) 2.47 (2.2 to 0.001 27.5) eGFR (mL/min/1.73 m ²) 96.3 (8.6.1 to 104.0 84.7 (73 3 to 0.001 96.9 (8.8.3 to 104.5 87.8 (7.49 to 0.001 94.4) Diabetes 538 (15.0) 90 (57.0) 0.001 75 (1.6) 1.5 (7.8.2) 0.001 R (4.6 (4.10) 74 (46.8) 0.160 1561 (3.39) 99 (4.5.9) 0.001 Dyshipidemia 1466 (41.0) 74 (46.8) 0.160 1561 (3.39) 99 (4.5.9) 0.001 Dyshipidemia 0.56 (1.4.1) 6.3 (39.9) 0.001 83 (1.8.1) 3 (1.4.1) 0.901 Abdominal obesity 498 (1.3.9) 400 (2.5.3) 0.001 75 (1.6.1) 15 (7.1) 0.004 BAD status 0.001 Dot (4.4) 8 (3.8) 0.433 (1.2 (1.3 0.2 (1.5) 15 (7.1) 0.004 BAD status 0.001 Dot (4.4) 8 (3.8) 0.433 (1.4) 0.999 Diabetes 0.36 (-1.2 to 0.8) -0.8 (-1.7 to 0.3) 0.001 0.1 (-1.0 to 1.4) -0.6 (-1.6 to 0.5) 0.001 Dyshipidemia 0.56 (4.1) 74 (4.8) 0.300 38 (1.8) 3 (1.4) 0.999 Diabetes 0.36 (-1.2 to 0.8) -0.8 (-1.7 to 0.3) 0.001 BAD status 0.001 Dot (4.4) 8 (3.1) 0.003 Actorial disorders 126 (5.6) 127 (1.33) 0.37 10 (0.4) 4 (3.1) 0.003 Actorial disorders 126 (5.6)	Physical activity			0.001			0.001
Moderate 324 (9.1) 16 (101) 328 (7.1) 5 (1.4) 6 (2.6) FBG (mmol/L) 5.5 (5.1 to 6.0) 6.2 (5.5 to 7.8) 0.001 5.4 (5.7 to 8.3) 0.08 (7.7 to 11.8) 0.001 FBG (mmol/L) 6.4 (5.1 to 8.2) 9.6 (6.8 to 15.4) 0.001 5.7 (5.4 to 6.0) 6.2 (5.7 to 7.4) 0.001 5.7 (5.4 to 6.0) 6.3 (5.7 to 8.1) 0.001 FIN (µL/mL) 5.2 (3.4 to 7.7) 6.5 (4.3 to 9.8) 0.001 5.7 (5.4 to 6.0) 6.3 (5.7 to 8.1) 0.001 FIN (µL/mL) 5.2 (3.4 to 7.7) 6.5 (7 to 9.8) 0.001 7.6 (6.9 to 8.3) 7.8 (7 to 8.7) 0.001 7.6 (6.9 to 8.3) 7.8 (7 to 8.7) 0.001 7.6 (6.9 to 8.3) 7.8 (7 to 8.7) 0.001 7.6 (6.9 to 8.3) 7.8 (7 to 8.7) 0.017 7.6 (5.9 to 8.3) 7.8 (7 to 8.7) 0.017 7.6 (5.9 to 8.3) 7.8 (7 to 8.7) 0.017 7.6 (5.9 to 8.3) 7.8 (7 to 8.7) 0.01 7.6 (5.9 to 8.3) 7.8 (7 to 8.7) 0.01 1.4 (1.2 to 1.3, 7) 0.01 TC (rmmol/L) 1.4 (1 to 2.1) 1.4 (1 to 2.1) 0.4 (1.1 to 2.2) 2.4 (2 to 2.3)	Low	2399 (67.1)	123 (77.8)		3/44 (81.4)	202 (95.7)	
High 854 (2.3) 19 (120) 526 (1.14) 6 (2.b) PBG (mmol/L) 5.5 (5.1 to 6.0) 62 (5.5 to 7.8) 0.001 6.4 (5.0 to 5.8) 6.2 (5.5 to 7.8) 0.001 6.4 (5.0 to 5.8) 6.2 (5.5 to 7.8) 0.001 6.4 (5.0 to 5.8) 6.2 (5.7 to 7.4) 0.001 5.7 (5.4 to 6.0) 6.3 (5.7 to 8.1) 0.001 FIN (µL/mL) 5.2 (3.4 to 7.7) 6.5 (4.3 to 9.8) 0.001 1.6 (4.6 to 8.8) 7.6 (5.1 to 3.4) 0.001 BP (mmHg) 1.3 (0.8 to 2.0) 2.1 (1.2 to 1.50) 0.001 7.6 (9.4 so 8.8) 7.8 (7 1 to 8.7) 0.001 DBP (mmHg) 1.3 (1.1 to 1.5) 1.3 (1.1 to 1.5) 0.001 7.6 (9 to 8.3) 7.8 (7 1 to 8.7) 0.001 TG (mmol/L) 1.3 (1.1 to 1.2) 1.4 (1.0 to 2.3) 1.4 (1.2 to 1.6) 1.4 (1.2 to	Moderate	324 (9.1)	16 (10.1)		328 (7.1)	3 (1.4)	
FBG (mmol/L) 5.5 (1: 10: 60) 6.2 (5.5 10: 7.8) 0.001 5.4 (5.0 10: 88) 6.2 (5.5 10: 8.8) 0.001 HbA1c (%) 5.7 (5.4 to 6.0) 6.2 (5.7 to 7.4) 0.001 5.7 (5.4 to 6.0) 6.3 (5.7 to 8.3) 0.001 HV(µ/mL) 5.2 (3.4 to 7.7) 6.5 (4.3 to 9.8) 0.001 1.5 (1.1 to 2.2) 2.2 (1.5 to 3.4) 0.001 FIN (µ/µ/mL) 5.2 (3.4 to 7.7) 6.5 (7.5 to 8.3) 0.001 1.5 (1.1 to 2.2) 2.2 (1.5 to 3.4) 0.001 SPP (mmHg) 134 (123 to 147) 146 (132 to 159) 0.001 1.5 (1.1 to 1.2) 2.2 (1.5 to 3.4) 0.001 DBP (mmHg) 78 (72 to 86) 85 (76 to 91) 0.001 76 (76 to 8.3) 76 (71 to 87) 0.001 DL (mmol/L) 1.3 (1.1 to 1.5) 1.3 (1.1 to 1.5) 0.045 1.4 (1.2 to 1.6) 1.4 (1.2 to 1.6) 0.201 TC (mmol/L) 1.4 (1.0 to 2.1) 1.6 (1.1 to 2.5) 0.006 1.3 (0.9 to 1.8) 1.6 (2.2 to 2.3) 0.001 TG (mmol/L) 1.4 (1.0 to 2.1) 6.6 (1.1 to 2.4) 0.001 2.7 (2.2 to 1.8) 3.2 (7.2 to 1.8) 3.2 (7.2 t	High	854 (23.9)	19 (12.0)	0.001	526 (11.4)	6 (2.6)	0.001
PhS (mm0/L) 6.4 (5, 16 8.2) 9.6 (8.5 16 3.4) 0.001 6.8 (5, 75 3.4) 0.001 6.8 (5, 75 3.4) 0.03 (5, 75 6.4) 0.001 FIN (µU/mL) 5.2 (3.4 to 7.7) 6.5 (4.3 to 9.8) 0.001 15 (1.1 to 2.2) 2.2 (1.5 to 3.4) 0.001 SPP (mmHg) 134 (123 to 147) 146 (132 to 159) 0.001 15 (1.1 to 2.2) 2.2 (1.5 to 3.4) 0.001 DB (mmHg) 134 (121 to 1.47) 146 (132 to 159) 0.001 176 (69 to 83) 78 (71 to 87) 0.001 TC (mmo/L) 1.3 (1.1 to 1.5) 0.045 1.4 (1.2 to 1.6) 1.4 (1.2 to 1.6) 0.237 LDL (mmo/L) 5.0 (4.4 to 5.7) 5.1 (4.4 to 5.8) 0.810 5.2 (4.5 to 5.9) 5.4 (8 to 1.0) 0.001 TG (mmo/L) 1.4 (1.0 to 2.1) 1.6 (1.1 to 2.5) 0.006 1.3 (0.9 to 1.8) 1.6 (2.2 to 2.3) 0.001 BMI (kg/m ²) 24.0 (21.9 to 26.2) 25.2 (23.2 to 0.001 23.7 (21.8 to 25.9) 24.7 (22.6 to 0.001 GFR (mL/min/1.73 m ²) 96.3 (86.1 to 10.40 84.7 (73.3 to 0.001 24.5 (18.3 to 14.5) 16.6 (2.1 0.3) 0.001 13	FBG (mmol/L)	5.5 (5.1 to 6.0)	6.2 (5.5 to 7.8)	0.001	5.4 (5.0 to 5.8)	6.2 (5.5 to 8.8)	0.001
HDAIL(19) 5.7 (5.4 to 6.0) 6.2 (5.7 to 7.4) 0.001 5.7 (5.4 to 6.0) 6.3 (5.7 to 6.1) 0.001 HOMA-R 1.3 (0.8 to 2.0) 2.1 (1.2 to 3.0) 0.001 1.5 (1.1 to 1.2, 2) 2.2 (1.5 to 3.4) 0.001 DBP (mmHg) 134 (123 to 147) 146 (132 to 147) 146 (132 to 147) 146 (132 to 147) 141 (1.2 to 1.6) 1.4 (1.2 to 1.6) 1.6 (2.2 to 3.4) 0.209 3.0 (2.5 to 3.6) 3.1 (2.6 to 3.7) 0.011 TC (mmol/L) 2.9 (2.4 to 3.4) 2.8 (2.3 to 3.4) 0.209 3.0 (2.5 to 3.6) 1.6 (2.2 to 2.3) 0.001 TC (mmol/L) 1.4 (1.0 to 2.1) 1.6 (1.1 to 2.2) 0.001 2.3 (2.1 to 1.6) 1.6 (2.2 to 2.3) 0.001 C (mmol/L) 1.4 (1.0 to 2.1) 1.6 (1.1 to 2.5) 0.001 2.4 (2.5 to 5.9) 5.5 (4.8 to 6.1) 0.001 D (11 (1.7 3.7) P6.3 (86.1 to 10.40 8.4 7 (7.3 to 0.001 9.5 (12.6) 2.7 (2.6 to 0.001 2.7 (2.6 to 0.001 2.7 (2.6 to 0.001 2.7 (2.6 to 0.001 </td <td>PBG (mmol/L)</td> <td>6.4 (5.1 to 8.2)</td> <td>9.6 (6.8 to 15.4)</td> <td>0.001</td> <td>6.8 (5.7 to 8.3)</td> <td>10.8 (7.7 to 11.8)</td> <td>0.001</td>	PBG (mmol/L)	6.4 (5.1 to 8.2)	9.6 (6.8 to 15.4)	0.001	6.8 (5.7 to 8.3)	10.8 (7.7 to 11.8)	0.001
Fink (µU/mL) 5.2 (3.4 to 7.7) 6.5 (4.3 to 7.9) 6.001 6.4 (4.8 to 8.8) 7.6 (5.3 to 11.3) 0.001 SPP (mmHg) 134 (123 to 147) 146 (132 to 159) 0.001 127 (117 to 144) 145 (133 to 161) 0.001 DBP (mmHg) 134 (12 to 15) 1.3 (1.1 to 1.5) 0.014 127 (117 to 144) 145 (133 to 161) 0.023 LDL (mmol/L) 1.3 (1.1 to 1.5) 1.3 (1.1 to 1.5) 0.045 1.4 (1.2 to 1.6) 1.4 (1.2 to 1.6) 0.237 LDL (mmol/L) 2.9 (2.4 to 3.4) 2.8 (2.3 to 3.4) 0.001 5.2 (4.5 to 5.5) 5.5 (4.8 to 6.1) 0.001 TC (mmol/L) 1.4 (1.0 to 2.1) 1.6 (1.1 to 2.5) 0.006 1.3 (0.9 to 1.8) 1.6 (2.2 to 2.3) 0.001 BMI (kg/m²) 24.0 (21.9 to 26.2) 2.2 (3.2 to 0.001 23.7 (21.8 to 25.9) 24.7 (22.6 to 0.001 27.5) eGFR (mL/min/1.73 m²) 96.3 (86.1 to 104.0 8.4 (73.3 to 0.001 96.9 (83.3 to 104.5) 8.7.8 (7.4 9 to 0.001 24.0 (21.9 to 25.9) 21.1 (2.5 to 3.6) 121 (57.3) 0.001 IR 506 (14.1) 63 (39.9) 0.01 87.7 (15.6) 15.2 (1.2 to 2.3) 121 (57.3) 0.001 <		5.7 (5.4 to 6.0)	6.2 (5.7 to 7.4)	0.001	5.7 (5.4 to 6.0)	6.3 (5.7 to 8.1)	0.001
HUM-HK 1.3 (0.8 to 2.0) 2.1 (1.2 to 3.0) 0.001 1.5 (1.1 to 2.2) 2.2 (1.5 to 3.4) 0.001 DBP (mmHg) 78 (72 to 86) 85 (76 to 91) 0.001 76 (69 to 83) 78 (71 to 87) 0.001 HDL (mmol/L) 1.3 (1.1 to 1.5) 1.3 (1.1 to 1.5) 0.44 to 5.8) 0.29 3.0 (2.5 to 3.6) 3.1 (2.6 to 3.7) 0.018 TC (mmol/L) 2.9 (2.4 to 3.4) 2.8 (2.3 to 3.4) 0.209 3.0 (2.5 to 3.6) 3.1 (2.6 to 3.7) 0.018 TC (mmol/L) 1.4 (1.0 to 2.1) 1.6 (1.1 to 5.5) 0.000 1.3 (0.9 to 1.8) 1.6 (2.2 to 2.3) 0.001 BMI (kg/m²) 24.0 (21.9 to 26.2) 25.2 (23.2 to 0.001 23.7 (21.8 to 25.9) 24.7 (22.6 to 0.001 Diabetes 538 (15.0) 90 (57.0) 0.001 552 (12.9) 24.7 (22.6 to 0.001 Picerension 1558 (43.6) 126 (79.7) 0.001 87.8 (74.9 to 0.001 Piseters 538 (15.0) 90 (57.0) 0.001 171 (37.3) 165 (78.2) 0.001 Piseters 538 (15.0) 126 (79.7) 0.001 171 (17.3) 165 (78.2) 0.001	FIN (µU/mL)	5.2 (3.4 to 7.7)	6.5 (4.3 to 9.8)	0.001	6.4 (4.6 to 8.8)	7.6 (5.3 to 11.3)	0.001
SbP (mmHg) 134 (12 sto 14/) 146 (13 zto 159) 0.001 12/ (17 to 144) 145 (13 sto 161) 0.001 DBP (mmHg) 78 (72 to 88) 85 (76 to 91) 0.004 76 (69 to 83) 78 (71 to 87) 0.001 HDL (mmol/L) 1.3 (1.1 to 1.5) 1.3 (1.1 to 1.5) 0.045 1.4 (1.2 to 1.6) 1.4 (1.2 to 1.6) 0.016 TC (mmol/L) 5.0 (4.4 to 5.7) 5.1 (4.4 to 5.8) 0.810 5.2 (4.5 to 3.7) 0.018 TC (mmol/L) 1.4 (1.0 to 2.1) 1.6 (1.1 to 2.5) 0.001 1.6 (2.2 to 2.3) 0.001 BMI (kg/m ²) 24.0 (21.9 to 26.2) 25.2 (2.3 to 0.001 23.7 (21.8 to 25.9) 24.7 (2.6 to 0.001 Ikg/m ² 24.6 (1.0) 7.3 to 0.001 830 (18.1) 91 (43.1) 0.001 R 506 (14.1) 63 (39.9) 0.001 830 (18.1) 91 (43.1) 0.001 Jpsipidemia 1466 (1.0) 74 (46.8) 0.160 1561 (33.9) 99 (46.9) 0.001 Gerrari obesity 498 (13.9) 40 (2.3) 0.001 75 (1.6)	HOMA-IR	1.3 (0.8 to 2.0)	2.1 (1.2 to 3.0)	0.001	1.5 (1.1 to 2.2)	2.2 (1.5 to 3.4)	0.001
Date Tel (72 to 26) DS (76 to 31) 0.001 Tel (12 to 1.6) 0.237 LDL (mmol/L) 1.3 (11 to 1.5) 1.4 (1.1 to 1.5) 0.045 1.4 (1.2 to 1.6) 0.237 LDL (mmol/L) 2.9 (2.4 to 3.4) 2.8 (2.3 to 3.4) 0.209 3.0 (2.5 to 3.6) 3.1 (2.6 to 3.7) 0.018 TC (mmol/L) 1.4 (1.0 to 2.1) 1.6 (1.1 to 2.5) 0.006 1.3 (0.9 to 1.8) 1.6 (2.2 to 2.3) 0.001 BMI (kg/m ²) 24.0 (2.1 ye to 2.2.) 25.2 (2.3.2 to 0.001 23.7 (21.8 to 25.9) 24.7 (22.6 to 0.001 Diabetes 5.38 (15.0) 90 (57.0) 0.001 96.9 (88.3 to 104.5) 87.8 (74.9 to 0.001 Pyslipidemia 1466 (41.0) 74 (44.8) 0.160 1561 (3.3) 99 (45.9) 0.001 Pyslipidemia 1466 (41.0) 74 (44.8) 0.160 1561 (3.3) 99 (45.9) 0.001 Gereral obesity 498 (13.9) 40 (25.3) 0.001 271.6. 15 (7.1) 0.001 Gereral obesity 498 (2.5) 15 (9.5) 0.001 75 (1.6)	SBP (mmHg)	134 (123 to 14/)	146 (132 to 159)	0.001	127 (117 to 144)	145(133 to 161)	0.001
HDL (mmol/L) 1.3 (1.1 to 1.5) 1.3 (1.1 to 1.5) 1.3 (1.1 to 1.5) 1.4 (1.2 to 1.6) 1.4 (1.2 to 1.6) 0.14 (1.2 to 1.6) 0.018 TC (mmol/L) 5.0 (4.4 to 5.7) 5.1 (4.4 to 5.8) 0.001 5.2 (4.5 to 5.9) 5.5 (4.8 to 6.1) 0.001 TG (mmol/L) 1.4 (1.0 to 2.1) 1.6 (1.1 to 2.5) 0.001 23.7 (21.8 to 25.9) 24.7 (22.6 to 0.001 BMI (kg/m²) 24.0 (21.9 to 26.2) 25.2 (23.2 to 0.001 96.9 (88.3 to 104.5 87.8 (74.9 to 0.001 Jbabetes 538 (15.0) 90 (57.0) 0.001 830 (18.1) 91 (43.1) 0.001 Jyslipidemia 1466 (41.0) 74 (46.8) 0.160 1561 (33.9) 99 (46.9) 0.001 Gestrointestinal disorders 452 (12.6) 12 (13.3) 0.807 538 (15.0) 15 (7.1) 0.001 Gestrointestinal disorders 452 (12.6) 11 (3.1) 7 (4.4) 0.350 83 (1.8) 3 (1.4) 0.999 Urological diseases <td< td=""><td></td><td>/8 (/2 to 86)</td><td>85 (76 to 91)</td><td>0.001</td><td>76 (69 to 83)</td><td>/8 (/1 to 8/)</td><td>0.001</td></td<>		/8 (/2 to 86)	85 (76 to 91)	0.001	76 (69 to 83)	/8 (/1 to 8/)	0.001
LDL (minib/L) 2.9 (2.4 to 3.4) 2.2 (2.3 to 3.4) 0.209 3.0 (2.5 to 3.6) 3.1 (2.6 to 3.7) 0.010 TC (mmol/L) 5.0 (4.4 to 5.7) 5.1 (4.4 to 5.8) 5.2 (4.5 to 5.9) 5.2 (5.1 t	HDL (mmol/L)	1.3 (1.1 to 1.5)	1.3 (1.1 to 1.5)	0.045	1.4 (1.2 to 1.6)	1.4 (1.2 to 1.6)	0.237
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	LDL (mmol/L)	2.9 (2.4 to 3.4)	2.8 (2.3 to 3.4)	0.209	$5.0 (2.5 \ 10 \ 5.0)$	3.1 (2.0 to 3.7)	0.018
Highings 1.4 (13 (0 ± 1)) 1.9 (1.1 (0 ± 2)) 0.001 1.3 (0.9 (0 1.6)) 1.6 (2.1 (0 ± 2.1)) 1.7 (1.2 (1.2 (0 ± 2.1)) 1.7 (1.2 (1.2 (0 ± 2.1)) 1.7 (1.2 (1.1 (1.1 (1.2 (1.1 (1.1 (1.1 (1.1	TC (mmol/L)	3.0 (4.4 (0 3.7))	$3.1 (4.4 \ 10 \ 3.6)$	0.010	3.2 (4.3 (0.5.9)	3.3 (4.0 10 0.1) 1.6 (2.2 to 2.2)	0.001
binn (kg/m) 24.0 (21.5 (0 20.2) 22.5 (21.3 (0 20.2)) 22.5 (21.3 (0 20.2)) 22.5 (21.3 (0 20.2)) 22.3 (21.3 (0 20.2)) 27.3 (20.0) 27.4 (20.0) 27.4 (20.0) 27.4 (20.0) 27.4 (20.0) 27.4 (20.	$\frac{10}{100} (\text{Inition/L})$	1.4 (1.0 to 2.1)	1.0 (1.1 LO 2.3)	0.000	1.5 (0.9 to 1.6)	1.0 (2.2 to 2.5)	0.001
eGFR (mL/min/1.73 m ²) 96.3 (86.1 to 104.0 84.7 (73.3 to 96.0) 0.001 96.9 (88.3 to 104.5 87.8 (74.9 to 94.4) 0.001 Diabetes 538 (15.0) 90 (57.0) 0.001 592 (12.9) 121 (57.3) 0.001 Hypertension 1558 (43.6) 126 (79.7) 0.001 1717 (37.3) 165 (78.2) 0.001 General obesity 498 (13.9) 40 (25.3) 0.001 2048 (44.5) 146 (69.2) 0.001 General obesity 760 (21.2) 55 (34.8) 0.001 2048 (44.5) 146 (69.2) 0.001 Gastrointestinal disorders 452 (12.6) 21 (13.3) 0.807 538 (15.0) 15 (7.1) 0.004 Respiratory diseases 112 (3.1) 7 (4.4) 0.350 83 (1.8) 3 (1.4) 0.999 Urological diseases 233 (6.5) 16 (10.1) 0.100 0.1 (-1.0 to 1.4) -0.6 (-1.6 to 0.5) 0.001 Normal BMD 2475 (69.2) 88 (55.7) 3378 (73.5) 129 (61.1) 0.001 Number 2156 95 2676 131	BMI (Kg/III)	24.0 (21.9 (0 20.2)	23.2 (23.2 10	0.001	25.7 (21.8 (0 25.9)	24.7 (22.0 10	0.001
96.0) 94.4) Diabetes 538 (15.0) 90 (57.0) 0.001 592 (12.9) 121 (57.3) 0.001 IR 550 6 (14.1) 63 (39.9) 0.001 830 (18.1) 91 (43.1) 0.001 Dyslipidemia 1466 (41.0) 74 (46.8) 0.160 1551 (33.9) 99 (46.9) 0.001 General obesity 498 (13.9) 40 (25.3) 0.001 2048 (44.5) 146 (69.2) 0.001 Abdominal obesity 760 (21.2) 55 (34.8) 0.001 75 (1.6) 15 (7.1) 0.001 Gastrointestinal disorders 452 (12.6) 21 (13.3) 0.807 538 (15.0) 15 (7.1) 0.001 Gastrointestinal disorders 233 (6.5) 16 (10.1) 0.100 201 (4.4) 8 (3.8) 0.863 7-score -0.3 (-1.2 to 0.8) -0.8 (-17 to 0.3) 0.001 0.1 (-1.0 to 1.4) -0.6 (-1.6 to 0.5) 0.01 Normal BMD 2475 (69.2) 88 (55.7) 3378 (73.5) 129 (61.1) 0.001 Number 2156 95 2676	eGFR (mL/min/1.73 m ²)	96.3 (86.1 to 104.0	84.7 (73.3 to	0.001	96.9 (88.3 to 104.5	87.8 (74.9 to	0.001
Diabetes 538 (15.0) 90 (57.0) 0.001 592 (12.9) 121 (57.3) 0.001 IR 506 (14.1) 63 (39.9) 0.001 830 (18.1) 91 (43.1) 0.001 Hypertension 1558 (43.6) 126 (79.7) 0.001 1717 (37.3) 165 (78.2) 0.001 General obesity 498 (13.9) 40 (25.3) 0.001 641 (13.9) 50 (23.7) 0.001 Abdominal obesity 760 (21.2) 55 (34.8) 0.001 75 (1.6) 15 (7.1) 0.001 Gastrointestinal disorders 452 (12.6) 21 (13.3) 0.807 538 (15.0) 15 (7.1) 0.046 Respiratory diseases 123 (6.5) 16 (10.1) 0.100 201 (4.4) 8 (3.8) 0.863 7-score -0.3 (-1.2 to 0.8) -0.8 (-1.7 to 0.3) 0.001 0.1 (-1.0 to 1.4) -0.6 (-1.6 to 0.5) 0.001 BMD status 0.001 2475 (69.2) 88 (55.7) 3378 (73.5) 129 (61.1) 0.002 Normal BMD 2475 (69.2) 63 (55 to 70) 0.001 53 (48 to 60)			96.0)			94.4)	
IR 506 (14.1) 63 (39.9) 0.001 830 (18.1) 91 (43.1) 0.001 Hypertension 1558 (43.6) 126 (79.7) 0.001 1717 (37.3) 165 (78.2) 0.001 Dyslipidemia 1466 (41.0) 74 (46.8) 0.160 1551 (33.9) 99 (46.9) 0.001 General obesity 498 (13.9) 40 (25.3) 0.001 641 (13.9) 50 (23.7) 0.001 Abdominal obesity 760 (21.2) 55 (34.8) 0.001 2048 (44.5) 146 (69.2) 0.001 Gastrointestinal disorders 452 (12.6) 21 (13.3) 0.807 538 (15.0) 15 (7.1) 0.046 Respiratory diseases 112 (3.1) 7 (4.4) 0.350 83 (1.8) 3 (1.4) 0.999 Urological diseases 233 (6.5) 16 (10.1) 0.100 0.21 (4.4) 8 (3.8) 0.863 7-score -0.3 (-1.2 to 0.8) -0.8 (55.7) 3378 (73.5) 129 (61.1) 0.001 Normal BMD 2475 (69.2) 88 (55.7) 3378 (73.5) 129 (61.1) 0.001	Diabetes	538 (15.0)	90 (57.0)	0.001	592 (12.9)	121 (57.3)	0.001
Hypertension 1558 (43.6) 126 (79.7) 0.001 1717 (37.3) 165 (78.2) 0.001 Dyslipidemia 1466 (41.0) 74 (46.8) 0.160 1561 (33.9) 99 (46.9) 0.001 General obesity 498 (13.9) 40 (25.3) 0.001 641 (13.9) 50 (23.7) 0.001 Gastrointestinal disorders 452 (12.6) 15 (9.5) 0.001 75 (1.6) 15 (7.1) 0.004 Respiratory diseases 112 (3.1) 7 (4.4) 0.350 83 (1.8) 3 (1.4) 0.999 Urological diseases 233 (6.5) 16 (10.1) 0.100 201 (4.4) 8 (3.8) 0.863 7-score -0.3 (-1.2 to 0.8) -0.8 (-1.7 to 0.3) 0.001 0.1 (-1.0 to 1.4) -0.6 (-1.6 to 0.5) 0.001 Normal BMD 2475 (69.2) 88 (55.7) 3378 (73.5) 129 (61.1) 0.001 Sosteoporosis 126 (3.5) 12 (7.6) 188 (4.1) 19 (9.0) 19 (9.0) Follow-up 126 (3.5) 12 (7.6) 188 (4.1) 19 (9.0) 1032 (22.4) 63 (25.9)<	IR	506 (14.1)	63 (39.9)	0.001	830 (18.1)	91 (43.1)	0.001
Dysipidemia 1466 (41.0) 74 (46.8) 0.160 1561 (33.9) 99 (46.9) 0.001 General obesity 498 (13.9) 40 (25.3) 0.001 641 (13.9) 50 (23.7) 0.001 Abdominal obesity 760 (21.2) 55 (34.8) 0.001 2048 (44.5) 146 (69.2) 0.001 Gastrointestinal disorders 452 (12.6) 21 (13.3) 0.807 538 (15.0) 15 (7.1) 0.046 Respiratory diseases 112 (3.1) 7 (4.4) 0.350 83 (1.8) 3 (1.4) 0.999 Urological diseases 233 (6.5) 16 (10.1) 0.100 201 (4.4) 8 (3.8) 0.863 7-score -0.3 (-1.2 to 0.8) -0.8 (-1.7 to 0.3) 0.001 0.1 (-1.0 to 1.4) -0.6 (-1.6 to 0.5) 0.001 Normal BMD 2475 (69.2) 88 (55.7) 3378 (73.5) 129 (61.1) 0.001 Steoperosis 126 (3.5) 12 (7.6) 188 (4.1) 19 (9.0) 5 Follow-up Number 2156 95 2676 131 Age (years) 54 (49 to 6	Hypertension	1558 (43.6)	126 (79.7)	0.001	1717 (37.3)	165 (78.2)	0.001
General obesity 498 (13.9) 40 (25.3) 0.001 641 (13.9) 50 (23.7) 0.001 Abdominal obesity 760 (21.2) 55 (34.8) 0.001 2048 (44.5) 146 (69.2) 0.001 Gastrointestinal disorders 452 (12.6) 21 (13.3) 0.807 538 (15.0) 15 (7.1) 0.004 Respiratory diseases 112 (3.1) 7 (4.4) 0.350 83 (1.8) 3 (1.4) 0.999 Urological diseases 233 (6.5) 16 (10.1) 0.100 201 (4.4) 8 (3.8) 0.863 T-score -0.3 (-1.2 to 0.8) -0.8 (-1.7 to 0.3) 0.001 0.1 (-1.0 to 1.4) -0.6 (-1.6 to 0.5) 0.001 Normal BMD 2475 (69.2) 88 (55.7) 3378 (73.5) 129 (61.1) 0.50 Osteopenia 976 (27.3) 58 (36.7) 1032 (22.4) 63 (29.9) 0.51 Follow-up 126 (3.5) 12 (7.6) 188 (4.1) 19 (9.0) 19 (9.0) Height loss at least 2 cm 345 (16.0) 28 (29.5) 0.001 53 (48 to 60) 65 (58 to 70) 0.001	Dyslipidemia	1466 (41.0)	74 (46.8)	0.160	1561 (33.9)	99 (46.9)	0.001
Abdominal obsity 760 (21.2) 55 (34.8) 0.001 2048 (44.5) 146 (69.2) 0.001 eGFR <60 mL/min/1.73 m²	General obesity	498 (13.9)	40 (25.3)	0.001	641 (13.9)	50 (23.7)	0.001
eGFR < 60 mL/min/1.73 m²	Abdominal obesity	760 (21.2)	55 (34.8)	0.001	2048 (44.5)	146 (69.2)	0.001
Gastrointestinal disorders 452 (12.6) 21 (13.3) 0.807 538 (15.0) 15 (7.1) 0.046 Respiratory diseases 112 (3.1) 7 (4.4) 0.350 83 (1.8) 3 (1.4) 0.999 Urological diseases 233 (6.5) 16 (10.1) 0.100 201 (4.4) 8 (3.8) 0.863 T-score -0.3 (-1.2 to 0.8) -0.8 (-1.7 to 0.3) 0.001 0.1 (-1.0 to 1.4) -0.6 (-1.6 to 0.5) 0.001 Normal BMD 2475 (69.2) 88 (55.7) 3378 (73.5) 129 (61.1) 0.001 Osteopenia 976 (27.3) 58 (36.7) 1032 (22.4) 63 (29.9) 0.001 Follow-up 126 (3.5) 12 (7.6) 188 (4.1) 19 (9.0) 54 (49 to 62) 63 (55 to 70) 0.001 53 (48 to 60) 65 (58 to 70) 0.001 Height loss at least 2 cm 345 (16.0) 28 (29.5) 0.002 519 (19.4) 32 (24.4) 0.176 Smokers 1165 (54.0) 42 (44.2) 0.073 10 (0.4) 4 (3.1) 0.001 Coffee drinkers 768 (35.6) 29 (30.5) 0.086 81 (3.0) 4 (3.1) 0.001	eGFR <60 mL/min/1.73 m ²	89 (2.5)	15 (9.5)	0.001	75 (1.6)	15 (7.1)	0.001
Respiratory diseases 112 (3.1) 7 (4.4) 0.350 83 (1.8) 3 (1.4) 0.999 Urological diseases 233 (6.5) 16 (10.1) 0.100 201 (4.4) 8 (3.8) 0.863 <i>T</i> -score -0.3 (-1.2 to 0.8) -0.8 (-1.7 to 0.3) 0.001 0.1 (-1.0 to 1.4) -0.6 (-1.6 to 0.5) 0.001 BMD status 0.001 0.001 0.01 (-1.0 to 1.4) -0.6 (-1.6 to 0.5) 0.001 Osteopenia 976 (27.3) 58 (36.7) 1032 (22.4) 63 (29.9) 0.001 Follow-up 126 (3.5) 12 (7.6) 188 (4.1) 19 (9.0) 1000 Follow-up 2156 95 2676 131 32 (24.4) 0.176 Mumber 2156 95 2676 131 0.001 Height loss at least 2 cm 345 (16.0) 28 (29.5) 0.002 519 (19.4) 32 (24.4) 0.176 Smokers 1165 (54.0) 42 (44.2) 0.073 10 (0.4) 4 (3.1) 0.001 Coffee drinkers 768 (35.6) 29 (30.5) 0.086 81 (3.0) 4 (3.1) 0.001 Coffee drinkers <td>Gastrointestinal disorders</td> <td>452 (12.6)</td> <td>21 (13.3)</td> <td>0.807</td> <td>538 (15.0)</td> <td>15 (7.1)</td> <td>0.046</td>	Gastrointestinal disorders	452 (12.6)	21 (13.3)	0.807	538 (15.0)	15 (7.1)	0.046
Urological diseases 233 (6.5) 16 (10.1) 0.100 201 (4.4) 8 (3.8) 0.863 <i>T</i> -score -0.3 (-1.2 to 0.8) -0.8 (-1.7 to 0.3) 0.001 0.1 (-1.0 to 1.4) -0.6 (-1.6 to 0.5) 0.001 BMD status 0.001 0.001 0.1 (-1.0 to 1.4) -0.6 (-1.6 to 0.5) 0.001 Normal BMD 2475 (69.2) 88 (55.7) 3378 (73.5) 129 (61.1) 0.001 Osteopenia 976 (27.3) 58 (36.7) 1032 (22.4) 63 (29.9) 0.001 Follow-up 126 (3.5) 12 (7.6) 188 (4.1) 19 (9.0) 19 (9.0) Follow-up 2156 95 2676 131 10 (0.4) 4 (3.1) 0.001 Height loss at least 2 cm 345 (16.0) 28 (29.5) 0.002 519 (19.4) 32 (24.4) 0.176 Smokers 1165 (54.0) 42 (42.2) 0.073 10 (0.4) 4 (3.1) 0.001 Coffee drinkers 768 (35.6) 29 (30.5) 0.086 81 (3.0) 4 (53.2) 0.103 Milk drinkers	Respiratory diseases	112 (3.1)	7 (4.4)	0.350	83 (1.8)	3 (1.4)	0.999
7-score -0.3 (-1.2 to 0.8) -0.8 (-1.7 to 0.3) 0.001 0.1 (-1.0 to 1.4) -0.6 (-1.6 to 0.5) 0.001 BMD status 0.001 0.001 0.001 0.001 0.001 Normal BMD 2475 (69.2) 88 (55.7) 3378 (73.5) 129 (61.1) 0.001 Osteopenia 976 (27.3) 58 (36.7) 1032 (22.4) 63 (29.9) 0.001 Follow-up 126 (3.5) 12 (7.6) 188 (4.1) 19 (9.0) 19.00 Follow-up 1256 95 2676 131 116 Age (years) 54 (49 to 62) 63 (55 to 70) 0.002 519 (19.4) 32 (24.4) 0.176 Smokers 1165 (54.0) 42 (44.2) 0.073 10 (0.4) 4 (3.1) 0.001 Alcohol drinkers 768 (35.6) 29 (30.5) 0.086 81 (3.0) 4 (3.1) 0.001 Physical activity 0.022 0.022 0.001 0.021 0.021 0.001 0.001 Low 1428 (66.2) 72 (75.8) 0.234 (83.5) 126 (96.2) 0.001 0.001 High 512 (23.7) 1	Urological diseases	233 (6.5)	16 (10.1)	0.100	201 (4.4)	8 (3.8)	0.863
Difference Difference <thdifferenc< th=""> Differenc Differenc<</thdifferenc<>	I-score	-0.3 (-1.2 to 0.8)	-0.8 (-1.7 to 0.3)	0.001	0.1 (-1.0 to 1.4)	-0.6 (-1.6 to 0.5)	0.001
Normal BMD 2475 (69.2) 88 (55.7) 3378 (73.5) 129 (61.1) Osteopenia 976 (27.3) 58 (36.7) 1032 (22.4) 63 (29.9) Osteoporosis 126 (3.5) 12 (7.6) 188 (4.1) 19 (9.0) Follow-up 1256 95 2676 131 Age (years) 54 (49 to 62) 63 (55 to 70) 0.001 53 (48 to 60) 65 (58 to 70) 0.001 Height loss at least 2 cm 345 (16.0) 28 (29.5) 0.002 519 (19.4) 32 (24.4) 0.176 Smokers 1165 (54.0) 42 (44.2) 0.073 10 (0.4) 4 (3.1) 0.003 Alcohol drinkers 768 (35.6) 29 (30.5) 0.086 81 (3.0) 4 (3.1) 0.001 Coffee drinkers 204 (5.7) 6 (3.8) 0.379 309 (6.7) 6 (3.8) 0.022 Milk drinkers 1831 (51.2) 84 (53.2) 0.684 2057 (44.7) 84 (53.2) 0.103 Physical activity 0.022 0.022 0.001 0.021 0.001 126		2475 (60.2)		0.001		120 (61 1)	0.001
Osteopenial Osteoporosis 976 (27.3) 58 (36.7) 1052 (22.4) 63 (29.9) Osteoporosis 126 (3.5) 12 (7.6) 188 (4.1) 19 (9.0) Follow-up Number 2156 95 2676 131 Age (years) 54 (49 to 62) 63 (55 to 70) 0.001 53 (48 to 60) 65 (58 to 70) 0.001 Height loss at least 2 cm 345 (16.0) 28 (29.5) 0.002 519 (19.4) 32 (24.4) 0.176 Smokers 1165 (54.0) 42 (44.2) 0.073 10 (0.4) 4 (3.1) 0.003 Alcohol drinkers 768 (35.6) 29 (30.5) 0.086 81 (3.0) 4 (3.1) 0.001 Coffee drinkers 204 (5.7) 6 (3.8) 0.379 309 (6.7) 6 (3.8) 0.022 Milk drinkers 1831 (51.2) 84 (53.2) 0.684 2057 (44.7) 84 (53.2) 0.103 Physical activity 0.022 0.001 0.001 0.001 0.001 Low 1428 (66.2) 72 (75.8) 2234 (83.5) 126 (96.2)		24/5 (09.2)	88 (55.7)		3378 (73.5)	129 (01.1)	
Follow-up 12 (7.5) 12 (7.5) 188 (4.1) 19 (9.0) Number 2156 95 2676 131 Age (years) 54 (49 to 62) 63 (55 to 70) 0.001 53 (48 to 60) 65 (58 to 70) 0.001 Height loss at least 2 cm 345 (16.0) 28 (29.5) 0.002 519 (19.4) 32 (24.4) 0.176 Smokers 1165 (54.0) 42 (44.2) 0.073 10 (0.4) 4 (3.1) 0.003 Alcohol drinkers 768 (35.6) 29 (30.5) 0.086 81 (3.0) 4 (3.1) 0.001 Coffee drinkers 204 (5.7) 6 (3.8) 0.379 309 (6.7) 6 (3.8) 0.022 Milk drinkers 1831 (51.2) 84 (53.2) 0.684 2057 (44.7) 84 (53.2) 0.103 Physical activity 0.022 0.001 201 (7.5) 3 (2.3) 0.001 Low 1428 (66.2) 72 (75.8) 2234 (83.5) 126 (96.2) 0.001 High 512 (23.7) 11 (11.6) 241 (9.0) 2 (1.5) 55 (5.2 to 6.0) 6.2 (5.5 to 7.8) 0.001 5.4 (5.1 to 5.9) 6.0 (5.3 to 8.1) <t< td=""><td>Osteoperasis</td><td>970 (27.3) 126 (2.5)</td><td>20 (20.7) 12 (7.6)</td><td></td><td>1052 (22.4)</td><td>10 (0.0)</td><td></td></t<>	Osteoperasis	970 (27.3) 126 (2.5)	20 (20.7) 12 (7.6)		1052 (22.4)	10 (0.0)	
Number 2156 95 2676 131 Age (years) 54 (49 to 62) 63 (55 to 70) 0.001 53 (48 to 60) 65 (58 to 70) 0.001 Height loss at least 2 cm 345 (16.0) 28 (29.5) 0.002 519 (19.4) 32 (24.4) 0.176 Smokers 1165 (54.0) 42 (44.2) 0.073 10 (0.4) 4 (3.1) 0.003 Alcohol drinkers 768 (35.6) 29 (30.5) 0.086 81 (3.0) 4 (3.1) 0.001 Coffee drinkers 204 (5.7) 6 (3.8) 0.379 309 (6.7) 6 (3.8) 0.022 Milk drinkers 1831 (51.2) 84 (53.2) 0.684 2057 (44.7) 84 (53.2) 0.103 Physical activity 0.022 0.022 0.001 0.001 0.001 Low 1428 (66.2) 72 (75.8) 2234 (83.5) 126 (96.2) 0.001 High 512 (23.7) 11 (11.6) 241 (9.0) 2 (1.5) 5 FBG (mmol/L) 5.5 (5.2 to 6.0) 6.2 (5.5 to 7.8) 0.001 5.4 (5.1 to 5.	Follow-up	120 (5.5)	12 (7.0)		100 (4.1)	19 (9.0)	
Number 2130 55 2070 151 Age (years) 54 (49 to 62) 63 (55 to 70) 0.001 53 (48 to 60) 65 (58 to 70) 0.001 Height loss at least 2 cm 345 (16.0) 28 (29.5) 0.002 519 (19.4) 32 (24.4) 0.176 Smokers 1165 (54.0) 42 (44.2) 0.073 10 (0.4) 4 (3.1) 0.003 Alcohol drinkers 768 (35.6) 29 (30.5) 0.086 81 (3.0) 4 (3.1) 0.001 Coffee drinkers 204 (5.7) 6 (3.8) 0.379 309 (6.7) 6 (3.8) 0.022 Milk drinkers 1831 (51.2) 84 (53.2) 0.684 2057 (44.7) 84 (53.2) 0.103 Physical activity 0.022 0.002 0.001 0.001 0.001 0.001 Low 1428 (66.2) 72 (75.8) 2234 (83.5) 126 (96.2) 0.001 High 512 (23.7) 11 (11.6) 241 (9.0) 2 (1.5) 55 (5.2 to 6.0) 6.2 (5.5 to 7.8) 0.001 5.4 (5.1 to 5.9) 6.0 (5.3 to 8.1) 0.001 PBG (mmol/L) 7.0 (5.1 to 9.1) 9.6 (6.8 to 15.4)	Number	2156	05		2676	121	
Height loss at least 2 cm 345 (16.0) 28 (29.5) 0.002 519 (19.4) 32 (24.4) 0.176 Smokers 1165 (54.0) 42 (44.2) 0.073 10 (0.4) 4 (3.1) 0.003 Alcohol drinkers 768 (35.6) 29 (30.5) 0.086 81 (3.0) 4 (3.1) 0.001 Coffee drinkers 204 (5.7) 6 (3.8) 0.379 309 (6.7) 6 (3.8) 0.022 Milk drinkers 1831 (51.2) 84 (53.2) 0.684 2057 (44.7) 84 (53.2) 0.103 Physical activity 0.022 0.002 0.001 0.021 0.001 0.001 Low 1428 (66.2) 72 (75.8) 2234 (83.5) 126 (96.2) 0.001 High 512 (23.7) 11 (11.6) 241 (9.0) 2 (1.5) 55 (5.2 to 6.0) 6.2 (5.5 to 7.8) 0.001 5.4 (5.1 to 5.9) 6.0 (5.3 to 8.1) 0.001 PBG (mmol/L) 7.0 (5.1 to 9.1) 9.6 (6.8 to 15.4) 0.001 7.1 (6.0 to 9.0) 11.1 (7.8 to 15.8) 0.001		2130 54 (49 to 62)	95 63 (55 to 70)	0.001	2070 53 (48 to 60)	131 65 (58 to 70)	0.001
Integrit loss at least 2 cm 345 (10.0) 28 (29.3) 0.002 319 (19.4) 32 (24.4) 0.170 Smokers 1165 (54.0) 42 (44.2) 0.073 10 (0.4) 4 (3.1) 0.003 Alcohol drinkers 768 (35.6) 29 (30.5) 0.086 81 (3.0) 4 (3.1) 0.001 Coffee drinkers 204 (5.7) 6 (3.8) 0.379 309 (6.7) 6 (3.8) 0.022 Milk drinkers 1831 (51.2) 84 (53.2) 0.684 2057 (44.7) 84 (53.2) 0.103 Physical activity 0.022 0.001 0.022 0.001 0.001 Low 1428 (66.2) 72 (75.8) 2234 (83.5) 126 (96.2) 0.001 High 512 (23.7) 11 (11.6) 241 (9.0) 2 (1.5) 55 (5.2 to 6.0) 6.2 (5.5 to 7.8) 0.001 5.4 (5.1 to 5.9) 6.0 (5.3 to 8.1) 0.001 PBG (mmol/L) 7.0 (5.1 to 9.1) 9.6 (6.8 to 15.4) 0.001 7.1 (6.0 to 9.0) 11.1 (7.8 to 15.8) 0.001	Hoight loss at loast 2 cm	345 (16 0)	28 (20 5)	0.001	510 (10 <i>I</i>)	22 (24 4)	0.001
Sinokers 1103 (34.0) 42 (44.2) 0.073 10 (0.4) 4 (3.1) 0.003 Alcohol drinkers 768 (35.6) 29 (30.5) 0.086 81 (3.0) 4 (3.1) 0.001 Coffee drinkers 204 (5.7) 6 (3.8) 0.379 309 (6.7) 6 (3.8) 0.022 Milk drinkers 1831 (51.2) 84 (53.2) 0.684 2057 (44.7) 84 (53.2) 0.103 Physical activity 0.022 0.001 0.001 0.001 0.001 0.001 Low 1428 (66.2) 72 (75.8) 2234 (83.5) 126 (96.2) 0.001 High 512 (23.7) 11 (11.6) 241 (9.0) 2 (1.5) 55 (5.2 to 6.0) 6.2 (5.5 to 7.8) 0.001 5.4 (5.1 to 5.9) 6.0 (5.3 to 8.1) 0.001 PBG (mmol/L) 7.0 (5.1 to 9.1) 9.6 (6.8 to 15.4) 0.001 7.1 (6.0 to 9.0) 11.1 (7.8 to 15.8) 0.001	Smokers	1165 (54 O)	20 (29.3)	0.002	10 (0 4)	52 (24.4) A (2.1)	0.170
Alcohol dinkers 708 (35.0) 29 (30.3) 0.000 81 (3.0) 4 (3.1) 0.001 Coffee drinkers 204 (5.7) 6 (3.8) 0.379 309 (6.7) 6 (3.8) 0.022 Milk drinkers 1831 (51.2) 84 (53.2) 0.684 2057 (44.7) 84 (53.2) 0.103 Physical activity 0.022 0.001 Low 1428 (66.2) 72 (75.8) 2234 (83.5) 126 (96.2) Moderate 216 (10.0) 12 (12.6) 201 (7.5) 3 (2.3) High 512 (23.7) 11 (11.6) 241 (9.0) 2 (1.5) FBG (mmol/L) 5.5 (5.2 to 6.0) 6.2 (5.5 to 7.8) 0.001 5.4 (5.1 to 5.9) 6.0 (5.3 to 8.1) 0.001 PBG (mmol/L) 7.0 (5.1 to 9.1) 9.6 (6.8 to 15.4) 0.001 7.1 (6.0 to 9.0) 11.1 (7.8 to 15.8) 0.001	Alcohol drinkors	768 (35.6)	42 (44.2)	0.075	10 (0.4) 81 (3.0)	4 (3.1)	0.003
Connect uniters 204 (0.7) 0 (0.07)	Coffee drinkers	204 (57)	29 (30.3) 6 (3.8)	0.000	309 (67)	4 (J.1) 6 (3.8)	0.001
Milk difficers 1631 (31.2) 64 (33.2) 0.064 2037 (44.7) 64 (33.2) 0.103 Physical activity 0.022 0.001 0.001 0.001 0.001 Low 1428 (66.2) 72 (75.8) 2234 (83.5) 126 (96.2) 0.001 Moderate 216 (10.0) 12 (12.6) 201 (7.5) 3 (2.3) High 512 (23.7) 11 (11.6) 241 (9.0) 2 (1.5) FBG (mmol/L) 5.5 (5.2 to 6.0) 6.2 (5.5 to 7.8) 0.001 5.4 (5.1 to 5.9) 6.0 (5.3 to 8.1) 0.001 PBG (mmol/L) 7.0 (5.1 to 9.1) 9.6 (6.8 to 15.4) 0.001 7.1 (6.0 to 9.0) 11.1 (7.8 to 15.8) 0.001	Milk drinkers	204 (J.7) 1921 (51 2)	0 (5.0) 84 (53.2)	0.579	2057 (44 7)	0 (5.0) 84 (53.2)	0.022
Low 1428 (66.2) 72 (75.8) 2234 (83.5) 126 (96.2) Moderate 216 (10.0) 12 (12.6) 201 (7.5) 3 (2.3) High 512 (23.7) 11 (11.6) 241 (9.0) 2 (1.5) FBG (mmol/L) 5.5 (5.2 to 6.0) 6.2 (5.5 to 7.8) 0.001 5.4 (5.1 to 5.9) 6.0 (5.3 to 8.1) 0.001 PBG (mmol/L) 7.0 (5.1 to 9.1) 9.6 (6.8 to 15.4) 0.001 7.1 (6.0 to 9.0) 11.1 (7.8 to 15.8) 0.001	Physical activity	1031 (31.2)	04 (33.2)	0.004	2037 (44.7)	04 (33.2)	0.105
Moderate 216 (10.0) 12 (12.6) 201 (7.5) 3 (2.3) High 512 (23.7) 11 (11.6) 241 (9.0) 2 (1.5) FBG (mmol/L) 5.5 (5.2 to 6.0) 6.2 (5.5 to 7.8) 0.001 5.4 (5.1 to 5.9) 6.0 (5.3 to 8.1) 0.001 PBG (mmol/L) 7.0 (5.1 to 9.1) 9.6 (6.8 to 15.4) 0.001 7.1 (6.0 to 9.0) 11.1 (7.8 to 15.8) 0.001		1428 (66.2)	72 (75 8)	0.022	2234 (83 5)	126 (96.2)	0.001
High 512 (23.7) 11 (11.6) 241 (9.0) 2 (1.5) FBG (mmol/L) 5.5 (5.2 to 6.0) 6.2 (5.5 to 7.8) 0.001 5.4 (5.1 to 5.9) 6.0 (5.3 to 8.1) 0.001 PBG (mmol/L) 7.0 (5.1 to 9.1) 9.6 (6.8 to 15.4) 0.001 7.1 (6.0 to 9.0) 11.1 (7.8 to 15.8) 0.001	Moderate	216 (10.2)	12 (126)		2237 (03.3)	3 (2 3)	
FBG (mmol/L) 5.5 (5.2 to 6.0) 6.2 (5.5 to 7.8) 0.001 5.4 (5.1 to 5.9) 6.0 (5.3 to 8.1) 0.001 PBG (mmol/L) 7.0 (5.1 to 9.1) 9.6 (6.8 to 15.4) 0.001 7.1 (6.0 to 9.0) 11.1 (7.8 to 15.8) 0.001	High	512 (22.7)	11 (11.6)		201 (7.5)	2 (2.5) 2 (1 5)	
PBG (mmol/L) 7.0 (5.1 to 9.1) 9.6 (6.8 to 15.4) 0.001 7.1 (6.0 to 9.0) 11.1 (7.8 to 15.8) 0.001	FBG (mmol/L)	5.5(5.2 to 6.0)	6.2 (5.5 to 7.8)	0.001	5.4 (5.1 to 5.9)	6.0 (5.3 to 8.1)	0.001
	PBG (mmol/L)	7.0 (5.1 to 9.1)	9.6 (6.8 to 15.4)	0.001	7.1 (6.0 to 9.0)	11.1 (7.8 to 15.8)	0.001

Table 1. (Continued)

	Men			Women		
	Without		р	Without		р
	retinopathy	With retinopathy	Value	retinopathy	With retinopathy	Value
HbA1c (%)	5.5 (5.2 to 5.8)	6.1 (5.5 to 7.2)	0.001	5.5 (5.3 to 5.8)	6.2 (5.6 to 7.4)	0.001
SBP (mmHg)	133 (122 to 144)	134 (144 to 154)	0.001	131 (118 to 145)	146 (136 to 157)	0.001
DBP (mmHg)	80 (73 to 87)	81 (74 to 95)	0.579	70 (77 to 84)	79 (71 to 85)	0.316
HDL (mmol/L)	1.3 (1.1 to 1.5)	1.2 (1.0 to 1.4)	0.027	1.4 (1.2 to 1.6)	1.3 (1.1 to 1.5)	0.001
LDL (mmol/L)	2.9 (2.4 to 3.3)	2.8 (2.3 to 3.3)	0.144	3.1 (2.6 to 3.7)	3.0 (2.5 to 3.6)	0.094
TC (mmol/L)	5.1 (4.5 to 5.8)	5.0 (4.3 to 5.6)	0.069	5.4 (4.7to 6.1)	5.3 (4.7 to 5.9)	0.162
TG (mmol/L)	1.5 (1.0 to 2.3)	1.7 (1.2 to 2.3)	0.166	1.4 (1.0 to 2.0.)	1.6 (1.2 to 2.4)	0.001
BMI (kg/m²)	24.0 (22.3 to 26.5)	26.8 (23.1 to	0.001	24.0 (22.1 to 26.2)	25.3 (22.4 to	0.001
		28.0)			27.8)	
eGFR (mL/min/1.73 m ²)	95.3 (89.4 to 105.0	86.7 (80.6 to	0.001	97.0 (91.6 to 101.6	88.3 (74.2 to	0.001
		92.5)			94.2)	
Diabetes	337 (15.6)	30 (31.6)	0.001	437 (16.3)	36 (27.5)	0.002
Hypertension	1006 (46.7)	78 (82.1)	0.001	1140 (42.6)	116 (88.5)	0.001
Dyslipidemia	1094 (50.7)	57 (60.0)	0.093	1230 (46.0)	68 (51.9)	0.209
General obesity	498 (13.9)	40 (25.3)	0.001	641 (13.9)	40 (25.3)	0.001
Abdominal obesity	704 (32.7)	57 (60.0)	0.001	1605 (60.0)	107 (81.7)	0.467
eGFR $<$ 60 mL/min/1.73 m ²	8 (0.4)	2 (2.1)	0.064	40 (1.5)	14 (10.7)	0.001
Gastrointestinal disorders	141 (6.5)	5 (5.3)	0.831	167 (6.2)	10 (7.6)	0.464
Respiratory diseases	40 (1.9)	3 (3.2)		18 (0.7)	1 (0.8)	0. 598
Urological diseases	137 (6.4)	13 (13.7)	0.010	94 (3.5)	6 (4.6)	0. 467
T-score ^a	–1.2 (–1.9 to –0.4)	–1.5 (–2.5 to	0.119	–0.9 (–1.7 to –0.1)	–1.6 (–2.2 to	0.001
		-0.4)			-0.8)	
BMD status ^a			0.022			0.001
Normal BMD	826 (69.2)	30 (36.1)		1158 (52.1)	30 (25.2)	
Osteopenia	841 (27.3)	32 (38.6)		890 (40.0)	65 (54.6)	
Osteoporosis	232 (3.5)	21 (25.3)		176 (7.9)	24 (20.2)	
Follow-up changing						
New smokers	159 (7.4)	7 (7.4)	0.999	6 (0.2)	2 (1.5)	0.050
New alcohol drinkers	184 (8.5)	11(11.6)	0.038	41 (1.5)	2 (1.5)	0.999
New diabetes	135 (6.3)	3 (3.2)	0.277	176 (6.6)	6 (4.6)	0.468
New hypertension	233 (10.8)	4 (4.2)	0.039	287 (10.7)	13(9.9)	0.885
New dyslipidemia	340 (15.8)	12 (12.6)	0. 473	273 (17.7)	17 (13.0)	0.195
New gastrointestinal disorders	94 (4.4)	4 (4.2)	0.999	108 (4.0)	5 (3.8)	0.999
New respiratory diseases	30 (1.4)	3 (3.2)	0.160	13 (0.5)	1 (0.8)	0.489
New urological diseases	98 (4.5)	8 (8.4)	0.084	75 (2.8)	5 (3.8)	0.421
General obesity changed	125 (5.8)	14(14.7)	0.002	162 (6.1)	14 (10.7)	0 .041
Abdominal obesity changed	386 (17.9)	21 (22.1)	0.174	687 (25.7)	23 (18.7)	0.077
eGFR <60 mL/min/1.73 m ²	36 (1.7)	7 (7.4)	0.002	48 (1.8)	12 (9.2)	0.001
cnanged						

HbA1c = glycated hemoglobin A1c; HOMA-IR = homeostasis model assessment of insulin resistance; SBP = systolic blood pressure; DBP = diastolic blood triglycerides; HDL = high-density lipoprotein cholesterol; LDL = low-density lipoprotein cholesterol; TC = total cholesterol; TG = total triglycerides; BMI = body mass index; eGFR = estimated glomerular filtration rate; IR = insulin resistance.

Data are median (IQR) for continuous variables and count (%) for categorical variables. The difference among groups was examined by Kruskal-Wallis test or chi-square test where appropriate.

^aA total of 4325 subjects followed the measurement of calcaneal quantitative ultrasound (men without retinopathy, 1899; menwith retinopathy, 83; women without retinopathy, 2224; women with retinopathy, 1119).

women, and men aged \geq 65 years, respectively (Supplemental Tables S2 and S3).

Retinal microvascular abnormalities and low BMD risk

In men aged \geq 65 years, compared with participants without retinal microvascular abnormalities, those with retinal microvascular abnormalities had significantly higher risk of low BMD even after adjustment for different confounders; the fully adjusted odds ratio (OR) was 2.506 (95% confidence interval [CI] 1.454–4.321; p = 0.001). However, no significant associations were

found between retinal microvascular abnormalities and low BMD risk in men aged <65 years and premenopausal or postmenopausal women (all p > 0.05) (Table 2).

Retinal microvascular abnormalities and vertebral fractures risk

As shown in Table 3, retinal microvascular abnormalities were associated with the risk of vertebral fractures in men aged \geq 65 years, OR was 2.475 (95% CI 1.085–5.646; 0.031). However, no significant associations were found between retinal

Table 2. Retinopathy and Low BMD Risk (OR [95% CI])

	Retinopathy				
	None	Present	p Value		
Men					
< 65 years ($n = 299$	98)				
No. of cases	2911	87			
Unadjusted	1.00	1.491 (0.957, 2.323)	0.077		
Model 1	1.00	1.336 (0.855, 2.089)	0.203		
Model 2	1.00	1.272 (0.811, 1.995)	0.295		
Model 3	1.00	1.421 (0.890, 2.268)	0.141		
\geq 65 years ($n =$ 737	7)				
No. of cases	666	71			
Unadjusted	1.00	1.539 (0.942, 2.515)	0.085		
Model 1	1.00	1.620 (0.987, 2.660)	0.056		
Model 2	1.00	1.899 (1.142, 3.158)	0.013		
Model 3	1.00	2.506 (1.454, 4.321)	0.001		
Women					
Premenopausal (n	= 2176)				
No. of cases	2147	29			
Unadjusted	1.00	1.753 (0.663, 4.641)	0.258		
Model 1	1.00	0.916 (0.325, 2.581)	0.868		
Model 2	1.00	0.918 (0.322, 2.621)	0.873		
Model 3	1.00	1.275 (0.413, 3.939)	0.673		
Postmenopausal ($n = 2633$)					
No. of cases	2451	182			
Unadjusted	1.00	1.079 (0.795, 1.463)	0.627		
Model 1	1.00	0.764 (0.556, 1.051)	0.098		
Model 2	1.00	0.764 (0.555, 1.053)	0.100		
Model 3	1.00	0.861 (0.618, 1.199)	0.376		

Data are ORs (95% Cl). Bold indicates statistically significant (p < 0.05). Each model included the following covariates for adjustment: model 1: age; model 2: model 1 + education, physical activity, smoking status, alcohol, coffee, milk, and bean products consumption; model 3: model 2 + diabetes, insulin resistance, hypertension, dyslipidemia, eGFR <60 mL/min/1.73 m², generalized and abdominal obesity, gastrointestinal disorders, respiratory diseases, and urological diseases.

microvascular abnormalities and vertebral fractures in premenopausal and postmenopausal women and men aged <65 years (all p > 0.05). When stratified by diabetes, in the withoutdiabetes group, men with retinal microvascular abnormalities had higher risk for vertebral fractures than without retinopathy (OR = 2.194; 95% CI = 1.097-4.389; p = 0.026) after adjusted confounding factor. However, the difference was not found in women. In the diabetes group, both in men and women, the risk for vertebral fractures between those with retinal microvascular abnormalities and those without were not significantly different. Stratified by hypertension, hypertensive men with retinopathy had higher risk for vertebral fractures than those without (OR = 2.034; 95% CI 1.163 - 3.559; p = 0.013), but the difference was not found among women. In the without-hypertension group, no associations were found between MVD and fracture both in men and women (Table 4).

Discussion

To our knowledge, the present study is the first attempt to explore the association between the presence of retinal microvascular abnormalities and BMD/vertebral fractures stratified by age, sex, menopausal status, diabetes, and hypertension in a large prospective study. In the baseline study, our team found that participants with retinal microvascular abnormalities have a higher risk of low BMD compared with participants without microvascular abnormalities after adjustment for confounders among men aged \geq 65 years. After participants' height were followed for an average of 2.93 years, results showed that risk for vertebral fractures (height loss of at least 2 cm) was 2.475 times higher compared with the participants without retinal microvascular abnormalities among men aged \geq 65 years. In addition, when stratified by diabetes, in no diabetic group, men with microvascular abnormalities had higher risk for vertebral fracture compared with participants without retinopathy. Stratified by hypertension, hypertensive men with microvascular abnormalities had a higher risk for vertebral fracture compared with participants without hypertension.

The current result showed that retinal microvascular abnormalities were associated with an increased risk of low BMD and vertebral fragile fracture(s). These findings are consistent with

Table 3. Retinopathy and Vertebral Risk (ORs [95%C	. [])
--	---------------

	None	Present	p Value	
Men				
< 65 years ($n = 19$	945)			
No. of cases	1888	57		
Unadjusted	1.00	1.690 (0.899, 3.177)	0.104	
Model 1	1.00	1.407 (0.743, 2.663)	0.294	
Model 2	1.00	1.499 (0.786, 2.861)	0.219	
Model 3	1.00	1.470 (0.752, 2.874)	0.260	
Model 4	1.00	1.403 (0.713, 2.760)	0.327	
\geq 65 (n = 306)				
No. of cases	268	38		
Unadjusted	1.00	2.079 (1.024, 4.222)	0.043	
Model 1	1.00	1.981 (0.966, 4.063)	0.062	
Model 2	1.00	2.277 (1.650, 4.867)	0.034	
Model 3	1.00	2.514 (1.117, 5.656)	0.026	
Model 4	1.00	2.475 (1.085, 5.646)	0.031	
Women				
Premenopausal (r	n = 1276)			
No. of cases	1267	9		
Unadjusted	1.00	1.552 (0.320, 7.525)	0.585	
Model 1	1.00	1.630 (0.335, 7.921)	0.545	
Model 2	1.00	1.358 (0.271, 6.798)	0.709	
Model 3	1.00	1.338 (0.248, 7.231)	0.735	
Model 4	1.00	1.387 (0.249, 7.728)	0.709	
Postmenopausal ($n = 1531$)				
No. of cases	1409	122		
Unadjusted	1.00	1.101 (0.716, 1.693)	0.662	
Model 1	1.00	1.008 (0.650, 1.563)	0.972	
Model 2	1.00	1.017 (0.654, 1.582)	0.940	
Model 3	1.00	0.995 (0.631, 1.571)	0.983	
Model 4	1.00	0.972 (0.613, 1.541)	0.904	

Data are ORs (95%CI). Bold indicates statistically significant (p < 0.05). Each model included the following covariates for adjustment: model 1: grouped age, baseline BMD; model 2: model 1 + education, physical activity, smoking status, alcohol, coffee, milk, and bean products consumption; model 3: model 2 + diabetes, insulin resistance, hypertension, dyslipidemia, eGFR <60 mL/min/1.73 m², generalized and abdominal obesity; model 4: model 3 + the new occurrence of smoking status, alcohol, diabetes, hypertension, dyslipidemia, and the change of generalized and abdominal obesity, eGFR <60 mL/min/1.73 m².

Table 4. Prevalence and ORs of Vertebral Fracture Among Different Sex Retinopathy Stratified by Diabetes and Hypertension

	Me	Men retinopathy		Women retinopathy	
	Without	With	Without	With	
No. without diabetes	1750	43	2225	59	
Prevalence %	15.5	32.6	19.1	25.4	
OR (95% CI) ^a	1.0 (ref)	2.194 (1.097, 4.389)	1.0 (ref)	1.010 (0.545, 1.874)	
p		0.026		0.974	
No. with diabetes	406	52	451	72	
Prevalence %	18.0	26.9	21.1	23.6	
OR (95% CI) ^a	1.0 (ref)	1.358 (0.651, 2.832)	1.0 (ref)	0.978 (0.501, 1.908)	
p		0.414		0.978	
No. without hypertension	1150	17	1536	15	
Prevalence %	15.3	23.5	18.2	33.3	
OR (95% CI) ^a	1.0 (ref)	1.349 (0.400, 4.551)	1.0 (ref)	1.625 (0.509, 5.189)	
р		0.630		0.412	
No. with hypertension	1006	78	1140	116	
Prevalence %	16.8	30.8	21.0	23.3	
OR (95% CI) ^a	1.0 (ref)	2.034 (1.163, 3.559)	1.0 (ref)	0.964 (0.593, 1.568)	
p		0.013		0.883	

^aAll ORs use the without-retinopathy cohort as the reference cohort (ref).

ORs were adjusted for age, baseline BMD, education, physical activity, smoking status, alcohol, coffee, milk, and bean products consumption, dyslipidemia, eGFR <60 mL/min/1.73 m², generalized and abdominal obesity, the new occurrence of smoking status, alcohol, diabetes, hypertension, dyslipidemia, and the change of generalized and abdominal obesity, eGFR <60 mL/min/1.73 m². In addition, adjustment for diabetes when stratified by hypertension and adjustment for hypertension when stratified by diabetes.

Bold indicates statistically significant (p < 0.05).

the notion that there is an association between vascular disease and bone. In this prospective study, not only baseline results showed that men aged \geq 65 years with MVD had higher risk of low BMD compared with participants without microvascular abnormalities, but also after 3-year follow-up visits, the men aged >65 years with MVD had a higher risk of fracture after adjustment for age, BMD, and other serial factors. This result indicated that MVD can lead to low BMD and fracture(s), although various common risk factors between BMD and MVD may lead to interaction of these two. MVD is an independent risk factor of vertebral fractures in old men. Shanbhogue and colleagues' analysis of adult type 1 diabetes patients with and without diabetic MVD compared with healthy control subjects, respectively, show that the presence of MVD was associated with deficits in cortical and trabecular bone volumetric BMD and microarchitecture that could partly explain the excess skeletal fragility.⁽³³⁾ Ivers and colleagues in a prospective study showed increased risk of fracture associated with diabetic retinopathy.⁽³⁾ However, in our study, we observed no diabetic men with retinopathy had an increased risk of vertebral fracture after adjusted age, BMD, and other confounding factors. The difference was not found in the diabetic subjects group. This heterogeneity may be because skeletal fragility often accompanies diabetes, but diabetes affects bone via many pathophysiological mechanisms, such as impairments in glucose metabolism and toxic effects of glucose oxidative derivatives, and via impairments in bone microvascular function and muscle endocrine function.⁽³⁴⁾ So we did not find a difference of risk for vertebral fracture in the diabetic subjects' group. Stratified by hypertension, only hypertensive men with microvascular abnormalities had higher risk for vertebral fracture compared with participants without retinopathy after adjustment for age, BMD, diabetes, and other confounders. The difference was not found in subjects without hypertension.

Current research confirms the study by Kusumbe and colleagues, which reported that the reduction of CD31hi/ Emcnhi vessels (a special subtype of capillaries that was almost unique to bone) and the concurrent decline of osteoprogenitor cells could potentially offer a compelling explanation for bone loss in mice during aging.⁽⁵⁾ CD31hi/Emcnhi endothelial cells mediate vasculature growth and provide niche signals for perivascular osteoprogenitors. Impaired vascular growth and bone loss were found in the genetically modified mice with disrupted Notch signaling in endothelial cells.⁽⁶⁾ Researchers have shown that improved angiogenesis in bone benefits bone formation. For example, platelet-derived growth factor-BB, exogenous or released by preosteoclasts, induces formation of the CD31hi/Emcnhi vessel subtype to promote the coupling of angiogenesis with bone formation;⁽³⁵⁾ exogenous factors DJ-1 induce osteogenesis and angiogenesis, both of which have properties that are essential for bone regeneration.⁽³⁶⁾ Our findings suggest that retinal microangiopathy may, as an index of the disturbed bone vascularity (declined CD31hi/Emcnhi vessels and impaired Notch signaling), be a mechanism leading to bone loss by diminished bone formation and, perhaps, excessive bone resorption, which affect BMD and lead to an increased risk for fractures in men aged \geq 65 years. Moreover, administration of antiangiogenic drugs are associated with adverse effects in vascular homeostasis and endocrine organs.⁽³⁷⁾ If our findings are confirmed in other samples, regular ophthalmoscopy and calcaneus quantitative ultrasound are needed among patients with antiangiogenic therapies.

However, the association between retinal microvascular abnormalities and low BMD risk and vertebral fractures has not been found in men aged <65 years and premenopausal and postmenopausal women. It is well known that women after menopause have accelerated bone loss, suggesting that estrogen deficiency plays a major role in this loss, which may

cover the effect of microvascular abnormalities on low BMD. This may partly explain why we fail to detect the association in postmenopausal women.

A strength of this work is that it was a prospective cohorts study, which included a large sample size of both men and women drawn from the general population rather than a specialized sample. The standardized identification of retinal microvascular abnormalities, detailed information collected on a range of risk factors, and potential confounders were collected. Our study examined the different associations of calcaneal BMD and fracture risk with microvascular abnormalities stratified by sex, age, menstrual status, diabetes, and hypertension. Limitations should also be stated. It was indirect to use height loss as a surrogate of vertebral fractures instead of imaging examination, since height loss may be due to weakening of the muscle groups, postural changes, disc degeneration, joint space narrowing, and spinal deformities. Also, the current study used calcaneal ultrasound T-scores, not by conventional dualenergy X-ray absorptiometry. Calcaneal quantitative ultrasound at commonly used cutoff thresholds do not definitively exclude or confirm DXA-determined osteoporosis.⁽³⁸⁾ Additionally, the inclusion of only persons who are Hans threatens the study's generalizability because patterns of bone density are known to vary by ethnicity.⁽³⁹⁾ Furthermore, many other variables potentially related to the risk of having low BMD, such as level of vitamin D, sex hormones, PTH, and other unknown or less clearly understood risk factors (for instance, genetic and inflammatory markers), may have played a role or modified the associations that we did not collect or assess because of the financial constraints. In addition, BMD was measured from a single bone site. However, the measurement of different sites of BMD in a multicenter epidemiologic study like this has not proven to be easy or practical, especially in remote mountainous regions.

In summary, our results provide evidence that retinal microvascular abnormalities are an independent risk factor of osteoporosis fracture in elderly men.

Disclosures

All authors state that they have no conflicts of interest.

Acknowledgments

This study was supported by grants from the Chinese Medical Association Foundation and Chinese Endocrine Society (12020240314), National Natural Science Foundation of China (81270874, 81570706), National Clinical Research Center for Metabolic Diseases (2013BAI09B13), the National Key New Drug Creation and Manufacturing Program of Ministry of Science and Technology (2012ZX09303006-001), Natural Science Foundation of Fujian Province (2011J06012, 2012J01322), and Provincial Health and Family Planning Commission of Fujian Province (2013-ZQN-ZD-3). This work is supported by the grants 2016YFC0901200 and 2016YFC0901203 from the Ministry of Science and Technology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank and acknowledge our colleagues and individuals who participated in this study.

Authors' roles: GC, PZ, JW, KT, FZ, WL, and HR conceived this article. KT and FZ wrote the first draft of the article, with further contributions from GC, PZ, JW, WL, HR, HH, JY, LC, HC, ML, JL, LLi,

XG, SP, LLin, JL, YB, WW, and GN. GC (principal investigator), with PZ, JW, and WL, applicants for the study, wrote the study protocol, obtained funding, designed the study, and interpreted the results. KT, LC, HC, ML, XG, and SP were responsible for data collection and delivery. KT, LC, HC, and ML managed data. TK and FZ did the statistical analysis, with support from GC, PZ, JW, and WL. All authors interpreted data, reviewed successive drafts, and approved the final version of the article.

References

- Lampropoulos CE, Papaioannou I, D'Cruz DP. Osteoporosis—a risk factor for cardiovascular disease? Nat Rev Rheumatol. 2012;8(10):587–98.
- Fajardo RJ. Is diabetic skeletal fragility associated with microvascular complications in bone? Curr Osteoporos Rep. 2017;15(1):1–8.
- 3. Ivers RQ, Cumming RG, Mitchell P, Peduto AJ. Diabetes and risk of fracture: the Blue Mountains Eye Study. Diabetes Care. 2001;24(7):1198–203.
- 4. Trias A, Fery A. Cortical circulation of long bones. J Bone Joint Surg Am. 1979;61(7):1052–9.
- 5. Kusumbe AP, Ramasamy SK, Adams RH. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature. 2014;507(7492):323–8.
- Ramasamy SK, Kusumbe AP, Wang L, Adams RH. Endothelial Notch activity promotes angiogenesis and osteogenesis in bone. Nature. 2014;507(7492):376–80.
- Wong TY, Klein R, Klein BE, Tielsch JM, Hubbard L, Nieto FJ. Retinal microvascular abnormalities and their relationship with hypertension, cardiovascular disease, and mortality. Surv Ophthalmol. 2001; 46(1):59–80.
- 8. Wong TY, Klein R, Couper DJ, et al. Retinal microvascular abnormalities and incident stroke: the Atherosclerosis Risk in Communities Study. Lancet. 2001;358(9288):1134–40.
- Nayak S, Roberts MS, Greenspan SL. Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Ann Intern Med. 2011;155(11):751–61.
- Cosman F, de Beur SJ, LeBoff MS, et al. Erratum to: Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2015;26(7):2045–7.
- 11. Masunari N, Fujiwara S, Kasagi F, Takahashi I, Yamada M, Nakamura T. Height loss starting in middle age predicts increased mortality in the elderly. J Bone Miner Res. 2012;27(1):138–45.
- 12. Xu W, Perera S, Medich D, et al. Height loss, vertebral fractures, and the misclassification of osteoporosis. Bone. 2011;48(2):307–11.
- Moayyeri A, Luben RN, Bingham SA, Welch AA, Wareham NJ, Khaw KT. Measured height loss predicts fractures in middle-aged and older men and women: the EPIC-Norfolk prospective population study. J Bone Miner Res. 2008;23(3):425–32.
- 14. Briot K, Legrand E, Pouchain D, Monnier S, Roux C. Accuracy of patient-reported height loss and risk factors for height loss among postmenopausal women. CMAJ. 2010;182(6):558–62.
- Yoshimura N, Kinoshita H, Takijiri T, et al. Association between height loss and bone loss, cumulative incidence of vertebral fractures and future quality of life: the Miyama study. Osteoporos Int. 2008;19(1):21–8.
- Siminoski K, Warshawski RS, Jen H, Lee K. The accuracy of historical height loss for the detection of vertebral fractures in postmenopausal women. Osteoporos Int. 2006;17(2):290–6.
- 17. Tobias JH, Hutchinson AP, Hunt LP, et al. Use of clinical risk factors to identify postmenopausal women with vertebral fractures. Osteoporos Int. 2007;18(1):35–43.
- Krege JH, Siminoski K, Adachi JD, Misurski DA, Chen P. A simple method for determining the probability a new vertebral fracture is present in postmenopausal women with osteoporosis. Osteoporos Int. 2006;17(3):379–86.
- 19. Siminoski K, Jiang G, Adachi JD, et al. Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures. Osteoporos Int. 2005;16(4):403–10.

- 20. Ismail AA, Cooper C, Felsenberg D, et al. Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. European Vertebral Osteoporosis Study Group. Osteoporos Int. 1999;9(3):206–13.
- 21. Huang C, Ross PD, Lydick E, Davis JW, Wasnich RD. Contributions of vertebral fractures to stature loss among elderly Japanese-American women in Hawaii. J Bone Miner Res. 1996;11(3):408–11.
- 22. Heaney RP. Pathophysiology of osteoporosis. Endocrinol Metab Clin N Am. 1998;27(2):255–65.
- 23. Losordo DW, Isner JM. Estrogen and angiogenesis: a review. Arterioscler Thromb Vasc Biol. 2001;21(1):6–12.
- Chen G, Chen L, Wen J, et al. Associations between sleep duration, daytime nap duration, and osteoporosis vary by sex, menopause, and sleep quality. J Clin Endocrinol Metab. 2014; 99(8):2869–77.
- Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9(8):1137–41.
- Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998;21(12):2191–2.
- Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.
- Wang T, Li M, Chen B, et al. Urinary bisphenol A (BPA) concentration associates with obesity and insulin resistance. J Clin Endocrinol Metab. 2012;97(2):E223–7.
- 29. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285(19):2486–97.

- WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157–63.
- Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet (London, England). Sep 24-30 2005;366(9491):1059–62. Epub 2005/09/27.
- Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139(2):137–47.
- Shanbhogue VV, Hansen S, Frost M, et al. Bone geometry, volumetric density, microarchitecture, and estimated bone strength assessed by HR-pQCT in adult patients with type 1 diabetes mellitus. J Bone Miner Res. 2015;30(12):2188–99.
- 34. Lecka-Czernik B. Diabetes, bone and glucose-lowering agents: basic biology. Diabetologia. 2017;60(7):1163–9.
- Xie H, Cui Z, Wang L, et al. PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis. Nat Med. 2014;20(11):1270–8.
- Kim JM, Shin HI, Cha SS, et al. DJ-1 promotes angiogenesis and osteogenesis by activating FGF receptor-1 signaling. Nat Commun. 2012;3:1296.
- 37. Cao Y. VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs. Nat Rev Endocrinol. 2014;10(9):530–9.
- Nayak S, Olkin I, Liu H, et al. Meta-analysis: accuracy of quantitative ultrasound for identifying patients with osteoporosis. Ann Intern Med. 2006;144(11):832–41.
- Ettinger B, Sidney S, Cummings SR, et al. Racial differences in bone density between young adult black and white subjects persist after adjustment for anthropometric, lifestyle, and biochemical differences. J Clin Endocrinol Metab. 1997;82(2):429–34.